

PatSeq Finder Sequence Search Results

Query Summary

Search Label WO_2017_116205_104 (BLASTP 40aa vs patseq-aa)
Query ID WO_2017_116205_104
Description -
Seq Length 40aa
Seq Type peptide
Sequence XXQGTFTSDXSKXXXXXXXXXXFXXWLLXXXXSSGQPPPSX

Results Summary Table

Patent Number	SEQ ID NO	Title	Assignee	Local % Id	Score (bits)	Ref. In Claims	Link
US_2012_0238493_A1	206	GLUCAGON ANALOGS EXHIBITING GIP RECEPTOR ACTIVITY	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION	54.1%	38.1	True	1
US_2012_0238493_A1	260	GLUCAGON ANALOGS EXHIBITING GIP RECEPTOR ACTIVITY	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION	54.1%	38.1		2

Details on Sequence Hits

1 - US_2012_0238493_A1 - SEQ ID NO 206

Patent Number [US 2012 0238493 A1](#)
SEQ ID NO [206](#)
Title GLUCAGON ANALOGS EXHIBITING GIP RECEPTOR ACTIVITY
Assignee INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Publication Date 2012-09-20
Priority Date 2010-12-22
Ref. In Claims True
Hit Sequence Length 39aa
Local % Id 54.1%
Score (bits) 38.1
Alignment Length 37

2 - US_2012_0238493_A1 - SEQ ID NO 260

Patent Number [US 2012 0238493 A1](#)
SEQ ID NO [260](#)
Title GLUCAGON ANALOGS EXHIBITING GIP RECEPTOR ACTIVITY
Assignee INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Publication Date 2012-09-20
Priority Date 2010-12-22
Ref. In Claims
Hit Sequence Length 39aa
Local % Id 54.1%
Score (bits) 38.1

Alignment Length

37

PatSeq Finder Sequence Search Results

Query Summary

Search Label WO_2017_116205_105 (BLASTP 40aa vs patseq-aa)
Query ID WO_2017_116205_105
Description -
Seq Length 40aa
Seq Type peptide
Sequence XXQGTFTSDYSKXLDEXXXKFVXWLLXXXXSSGQPPPSX

Results Summary Table

Patent Number	SEQ ID NO	Title	Assignee	Local % Id	Score (bits)	Ref. In Claims	Link
CA_2933701_A1	37	MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF		67.6%	52.4		1
US_2011_0288003_A1	1,039	AMIDE BASED GLUCAGON AND SUPERFAMILY PEPTIDE PRODRUGS	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION	70.3%	52.4	True	2
US_2011_0288003_A1	1,057	AMIDE BASED GLUCAGON AND SUPERFAMILY PEPTIDE PRODRUGS	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION	70.3%	52.4	True	3
US_2012_0322725_A1	139	GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY		70.3%	52.4	True	4
US_2012_0322725_A1	157	GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY		70.3%	52.4	True	5
US_2013_0116172_A1	1,039	GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN COUPLED RECEPTOR ACTIVITY	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION; MARCADIA BIOTECH INC	70.3%	52.4	True	6
US_2013_0116172_A1	1,057	GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN COUPLED RECEPTOR ACTIVITY	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION; MARCADIA BIOTECH INC	70.3%	52.4	True	7
US_2013_0123178_A1	1,039	GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY		70.3%	52.4	True	8
US_2013_0123178_A1	1,057	GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE		70.3%	52.4	True	9

		RECEPTOR ACTIVITY					
US_2013_0123462_A1	1,039	AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS		70.3%	52.4	True	10
US_2013_0123462_A1	1,057	AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS		70.3%	52.4	True	11
US_2013_0157934_A1	1,039	Glucagon Superfamily Peptides Exhibiting Glucocorticoid Receptor Activity	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION	70.3%	52.4	True	12
US_2013_0157934_A1	1,057	Glucagon Superfamily Peptides Exhibiting Glucocorticoid Receptor Activity	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION	70.3%	52.4	True	13
US_2014_0107021_A1	139	GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY		70.3%	52.4		14
US_2014_0107021_A1	157	GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY		70.3%	52.4		15
US_2014_0212419_A1	839	ESTER-BASED INSULIN PRODRUGS	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION	70.3%	52.4		16
US_2014_0212419_A1	857	ESTER-BASED INSULIN PRODRUGS	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION	70.3%	52.4		17
US_2015_0320871_A1	1,039	Glucagon Superfamily Peptides Exhibiting Nuclear Hormone Receptor Activity		70.3%	52.4	True	18
US_2015_0320871_A1	1,057	Glucagon Superfamily Peptides Exhibiting Nuclear Hormone Receptor Activity		70.3%	52.4	True	19
US_8551946_B2	139	Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity		70.3%	52.4		20
US_8551946_B2	157	Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity		70.3%	52.4		21
US_8778872_B2	1,039	Amide based glucagon superfamily peptide prodrugs		70.3%	52.4	True	22
US_8778872_B2	1,057	Amide based glucagon superfamily peptide prodrugs		70.3%	52.4	True	23
US_8859491_B2	1,039	Glucagon superfamily peptides exhibiting glucocorticoid receptor activity	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION	70.3%	52.4	True	24
US_8859491_B2	1,057	Glucagon superfamily peptides exhibiting glucocorticoid receptor activity	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION	70.3%	52.4	True	25
US_8969288_B2	1,039	Amide based glucagon and superfamily peptide prodrugs	INDIANA UNIVERSITY RESEARCH AND	70.3%	52.4	True	26

			TECHNOLOGY CORPORATION				
US_8969288_B2	1,057	Amide based glucagon and superfamily peptide prodrugs	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION	70.3%	52.4	True	27

Details on Sequence Hits

1 - CA_2933701_A1 - SEQ ID NO 37

Patent Number [CA 2933701 A1](#)
SEQ ID NO [37](#)
Title MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF
Assignee
Publication Date 2015-06-25
Priority Date 2013-12-18
Ref. In Claims
Hit Sequence Length 39aa
Local % Id 67.6%
Score (bits) 52.4
Alignment Length 37

2 - US_2011_0288003_A1 - SEQ ID NO 1039

Patent Number [US 2011_0288003 A1](#)
SEQ ID NO [1,039](#)
Title AMIDE BASED GLUCAGON AND SUPERFAMILY PEPTIDE PRODRUGS
Assignee INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Publication Date 2011-11-24
Priority Date 2008-12-19
Ref. In Claims True
Hit Sequence Length 39aa
Local % Id 70.3%
Score (bits) 52.4
Alignment Length 37

3 - US_2011_0288003_A1 - SEQ ID NO 1057

Patent Number [US 2011_0288003 A1](#)
SEQ ID NO [1,057](#)
Title AMIDE BASED GLUCAGON AND SUPERFAMILY PEPTIDE PRODRUGS
Assignee INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Publication Date 2011-11-24
Priority Date 2008-12-19
Ref. In Claims True
Hit Sequence Length 39aa
Local % Id 70.3%
Score (bits) 52.4
Alignment Length 37

4 - US_2012_0322725_A1 - SEQ ID NO 139

Patent Number [US 2012 0322725 A1](#)
SEQ ID NO [139](#)
Title GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY
Assignee
Publication Date 2012-12-20
Priority Date 2010-01-27
Ref. In Claims True
Hit Sequence Length 39aa
Local % Id 70.3%
Score (bits) 52.4
Alignment Length 37

5 - US_2012_0322725_A1 - SEQ ID NO 157

Patent Number [US 2012 0322725 A1](#)
SEQ ID NO [157](#)
Title GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY
Assignee
Publication Date 2012-12-20
Priority Date 2010-01-27
Ref. In Claims True
Hit Sequence Length 39aa
Local % Id 70.3%
Score (bits) 52.4
Alignment Length 37

6 - US_2013_0116172_A1 - SEQ ID NO 1039

Patent Number [US 2013 0116172 A1](#)
SEQ ID NO [1,039](#)
Title GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY
Assignee INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION; MARCADIA BIOTECH INC
Publication Date 2013-05-09
Priority Date 2010-05-13
Ref. In Claims True
Hit Sequence Length 39aa
Local % Id 70.3%
Score (bits) 52.4
Alignment Length 37

7 - US_2013_0116172_A1 - SEQ ID NO 1057

Patent Number [US 2013 0116172 A1](#)
SEQ ID NO [1,057](#)
Title GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY

Assignee	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION; MARCADIA BIOTECH INC
Publication Date	2013-05-09
Priority Date	2010-05-13
Ref. In Claims	True
Hit Sequence Length	39aa
Local % Id	70.3%
Score (bits)	52.4
Alignment Length	37

8 - [US_2013_0123178_A1](#) - SEQ ID NO 1039

Patent Number	US_2013_0123178_A1
SEQ ID NO	1.039
Title	GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY
Assignee	
Publication Date	2013-05-16
Priority Date	2010-05-13
Ref. In Claims	True
Hit Sequence Length	39aa
Local % Id	70.3%
Score (bits)	52.4
Alignment Length	37

9 - [US_2013_0123178_A1](#) - SEQ ID NO 1057

Patent Number	US_2013_0123178_A1
SEQ ID NO	1.057
Title	GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY
Assignee	
Publication Date	2013-05-16
Priority Date	2010-05-13
Ref. In Claims	True
Hit Sequence Length	39aa
Local % Id	70.3%
Score (bits)	52.4
Alignment Length	37

10 - [US_2013_0123462_A1](#) - SEQ ID NO 1039

Patent Number	US_2013_0123462_A1
SEQ ID NO	1.039
Title	AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
Assignee	
Publication Date	2013-05-16
Priority Date	2010-06-24
Ref. In Claims	True
Hit Sequence Length	39aa
Local % Id	70.3%
Score (bits)	52.4

Alignment Length 37

11 - US_2013_0123462_A1 - SEQ ID NO 1057

Patent Number [US 2013 0123462 A1](#)
SEQ ID NO [1.057](#)
Title AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
Assignee
Publication Date 2013-05-16
Priority Date 2010-06-24
Ref. In Claims True
Hit Sequence Length 39aa
Local % Id 70.3%
Score (bits) 52.4
Alignment Length 37

12 - US_2013_0157934_A1 - SEQ ID NO 1039

Patent Number [US 2013 0157934 A1](#)
SEQ ID NO [1.039](#)
Title Glucagon Superfamily Peptides Exhibiting Glucocorticoid Receptor Activity
Assignee INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Publication Date 2013-06-20
Priority Date 2011-11-17
Ref. In Claims True
Hit Sequence Length 39aa
Local % Id 70.3%
Score (bits) 52.4
Alignment Length 37

13 - US_2013_0157934_A1 - SEQ ID NO 1057

Patent Number [US 2013 0157934 A1](#)
SEQ ID NO [1.057](#)
Title Glucagon Superfamily Peptides Exhibiting Glucocorticoid Receptor Activity
Assignee INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Publication Date 2013-06-20
Priority Date 2011-11-17
Ref. In Claims True
Hit Sequence Length 39aa
Local % Id 70.3%
Score (bits) 52.4
Alignment Length 37

14 - US_2014_0107021_A1 - SEQ ID NO 139

Patent Number [US 2014 0107021 A1](#)
SEQ ID NO [139](#)
Title GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY
Assignee

Publication Date 2014-04-17
Priority Date 2010-01-27
Ref. In Claims
Hit Sequence Length 39aa
Local % Id 70.3%
Score (bits) 52.4
Alignment Length 37

15 - US_2014_0107021_A1 - SEQ ID NO 157

Patent Number [US 2014 0107021 A1](#)
SEQ ID NO [157](#)
Title GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY
Assignee
Publication Date 2014-04-17
Priority Date 2010-01-27
Ref. In Claims
Hit Sequence Length 39aa
Local % Id 70.3%
Score (bits) 52.4
Alignment Length 37

16 - US_2014_0212419_A1 - SEQ ID NO 839

Patent Number [US 2014 0212419 A1](#)
SEQ ID NO [839](#)
Title ESTER-BASED INSULIN PRODRUGS
Assignee INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Publication Date 2014-07-31
Priority Date 2008-01-30
Ref. In Claims
Hit Sequence Length 39aa
Local % Id 70.3%
Score (bits) 52.4
Alignment Length 37

17 - US_2014_0212419_A1 - SEQ ID NO 857

Patent Number [US 2014 0212419 A1](#)
SEQ ID NO [857](#)
Title ESTER-BASED INSULIN PRODRUGS
Assignee INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Publication Date 2014-07-31
Priority Date 2008-01-30
Ref. In Claims
Hit Sequence Length 39aa
Local % Id 70.3%
Score (bits) 52.4
Alignment Length 37

18 - US_2015_0320871_A1 - SEQ ID NO 1039

Patent Number	US 2015 0320871 A1
SEQ ID NO	1,039
Title	Glucagon Superfamily Peptides Exhibiting Nuclear Hormone Receptor Activity
Assignee	
Publication Date	2015-11-12
Priority Date	2010-05-13
Ref. In Claims	True
Hit Sequence Length	39aa
Local % Id	70.3%
Score (bits)	52.4
Alignment Length	37

19 - US_2015_0320871_A1 - SEQ ID NO 1057

Patent Number	US 2015 0320871 A1
SEQ ID NO	1,057
Title	Glucagon Superfamily Peptides Exhibiting Nuclear Hormone Receptor Activity
Assignee	
Publication Date	2015-11-12
Priority Date	2010-05-13
Ref. In Claims	True
Hit Sequence Length	39aa
Local % Id	70.3%
Score (bits)	52.4
Alignment Length	37

20 - US_8551946_B2 - SEQ ID NO 139

Patent Number	US 8551946 B2
SEQ ID NO	139
Title	Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
Assignee	
Publication Date	2013-10-08
Priority Date	2010-01-27
Ref. In Claims	
Hit Sequence Length	39aa
Local % Id	70.3%
Score (bits)	52.4
Alignment Length	37

21 - US_8551946_B2 - SEQ ID NO 157

Patent Number	US 8551946 B2
SEQ ID NO	157
Title	Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
Assignee	
Publication Date	2013-10-08
Priority Date	2010-01-27

Ref. In Claims

Hit Sequence Length	39aa
Local % Id	70.3%
Score (bits)	52.4
Alignment Length	37

22 - [US_8778872_B2](#) - SEQ ID NO 1039

Patent Number	US 8778872 B2
SEQ ID NO	1,039
Title	Amide based glucagon superfamily peptide prodrugs
Assignee	
Publication Date	2014-07-15
Priority Date	2010-06-24
Ref. In Claims	True
Hit Sequence Length	39aa
Local % Id	70.3%
Score (bits)	52.4
Alignment Length	37

23 - [US_8778872_B2](#) - SEQ ID NO 1057

Patent Number	US 8778872 B2
SEQ ID NO	1,057
Title	Amide based glucagon superfamily peptide prodrugs
Assignee	
Publication Date	2014-07-15
Priority Date	2010-06-24
Ref. In Claims	True
Hit Sequence Length	39aa
Local % Id	70.3%
Score (bits)	52.4
Alignment Length	37

24 - [US_8859491_B2](#) - SEQ ID NO 1039

Patent Number	US 8859491 B2
SEQ ID NO	1,039
Title	Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
Assignee	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Publication Date	2014-10-14
Priority Date	2011-11-17
Ref. In Claims	True
Hit Sequence Length	39aa
Local % Id	70.3%
Score (bits)	52.4
Alignment Length	37

25 - US_8859491_B2 - SEQ ID NO 1057

Patent Number	US 8859491 B2
SEQ ID NO	1,057
Title	Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
Assignee	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Publication Date	2014-10-14
Priority Date	2011-11-17
Ref. In Claims	True
Hit Sequence Length	39aa
Local % Id	70.3%
Score (bits)	52.4
Alignment Length	37

26 - US_8969288_B2 - SEQ ID NO 1039

Patent Number	US 8969288 B2
SEQ ID NO	1,039
Title	Amide based glucagon and superfamily peptide prodrugs
Assignee	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Publication Date	2015-03-03
Priority Date	2008-12-19
Ref. In Claims	True
Hit Sequence Length	39aa
Local % Id	70.3%
Score (bits)	52.4
Alignment Length	37

27 - US_8969288_B2 - SEQ ID NO 1057

Patent Number	US 8969288 B2
SEQ ID NO	1,057
Title	Amide based glucagon and superfamily peptide prodrugs
Assignee	INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Publication Date	2015-03-03
Priority Date	2008-12-19
Ref. In Claims	True
Hit Sequence Length	39aa
Local % Id	70.3%
Score (bits)	52.4
Alignment Length	37

PatSeq Finder Sequence Search Results

Query Summary

Search Label	WO_2017_116205_31 (BLASTP 29aa vs patseq-aa)
Query ID	WO_2017_116205_31
Description	-
Seq Length	29aa

Seq Type peptide
Sequence HXQGTFTSDYSKYLDEKACKEFVQWLLAQ

Results Summary Table

Patent Number	SEQ ID NO	Title	Assignee	Local % Id	Score (bits)	Ref. In Claims	Link
---------------	-----------	-------	----------	------------	--------------	----------------	------

Details on Sequence Hits

PatSeq Finder Sequence Search Results

Query Summary

Search Label WO_2017_116205_12 (BLASTP 41aa vs patseq-aa)
Query ID WO_2017_116205_12
Description -
Seq Length 41aa
Seq Type peptide
Sequence XGEGTFISDLSKYMDEQAVQLFVEWLMAGGPSSGAPPPSHG

Results Summary Table

Patent Number	SEQ ID NO	Title	Assignee	Local % Id	Score (bits)	Ref. In Claims	Link
US_8673860_B2	1,065	Extended recombinant polypeptides and compositions comprising same	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC	77.5%	77		1
US_8673860_B2	1,050	Extended recombinant polypeptides and compositions comprising same	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC	77.5%	70.5		2
US_8957021_B2	886	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	70.5		3
US_8673860_B2	1,051	Extended recombinant polypeptides and compositions comprising same	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC	77.5%	70.1		4
US_8957021_B2	882	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	70.1		5
US_8957021_B2	1,162	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	70.5		6
US_8957021_B2	1,164	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	70.5		7
US_8673860_B2	1,060	Extended recombinant polypeptides and compositions comprising same	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC	77.5%	73.2		8
US_8957021_B2	898	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	73.2		9

US_8673860_B2	1,054	Extended recombinant polypeptides and compositions comprising same	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC	77.5%	72.8		10
US_8673860_B2	1,052	Extended recombinant polypeptides and compositions comprising same	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC	77.5%	71.2		11
US_8957021_B2	884	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	71.2	True	12
US_8673860_B2	1,061	Extended recombinant polypeptides and compositions comprising same	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC	77.5%	73.2		13
US_8957021_B2	900	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	73.2		14
US_8957021_B2	892	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	72.8		15
US_8957021_B2	1,178	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	73.6		16
US_8673860_B2	1,057	Extended recombinant polypeptides and compositions comprising same	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC	77.5%	72.8		17
US_2014_0107019_A1	71	ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION	AMYLIN PHARMACEUTICALS INC; AMYLIN PHARMACEUTICALS LLC	77.5%	68.6	True	18
US_2015_0133373_A1	71	TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES	AMYLIN PHARMACEUTICALS INC; ASTRAZENECA PHARMACEUTICALS LP; AMYLIN PHARMACEUTICALS LLC	77.5%	68.6	True	19
WO_2012_050923_A2	71	ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION		77.5%	68.6	True	20
WO_2013_148966_A1	71	TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES		77.5%	68.6	True	21
US_9089538_B2	10	Peptide conjugates of GLP-1 receptor agonists and gastrin and their use	ZEALAND PHARMA A/S	77.5%	67.4		22
US_8957021_B2	1,204	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	73.2		23
US_8957021_B2	1,170	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	73.2		24
US_8957021_B2	1,180	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	73.2		25
US_8957021_B2	1,196	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	73.2		26
US_8957021_B2	1,206	Glucose-regulating	AMUNIX INC; AMUNIX	77.5%	73.2		27

		polypeptides and methods of making and using same	OPERATING INC				
US_2014_0107019_A1	55	ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION	AMYLIN PHARMACEUTICALS INC; AMYLIN PHARMACEUTICALS LLC	77.5%	68.2	True	28
US_2015_0133373_A1	55	TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES	AMYLIN PHARMACEUTICALS INC; ASTRAZENECA PHARMACEUTICALS LP; AMYLIN PHARMACEUTICALS LLC	77.5%	68.2	True	29
WO_2012_050923_A2	55	ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION		77.5%	68.2	True	30
WO_2013_148966_A1	55	TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES		77.5%	68.2	True	31
US_8673860_B2	1,053	Extended recombinant polypeptides and compositions comprising same	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC	77.5%	72.4		32
US_8673860_B2	1,062	Extended recombinant polypeptides and compositions comprising same	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC	77.5%	72.8		33
US_8957021_B2	902	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	72.8		34
US_8957021_B2	1,182	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	72.8		35
US_8957021_B2	1,190	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	71.6		36
US_8957021_B2	1,208	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	73.2		37
US_8957021_B2	1,188	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	71.6		38
US_8957021_B2	1,202	Glucose-regulating polypeptides and methods of making and using same	AMUNIX INC; AMUNIX OPERATING INC	77.5%	72.8		39
US_2014_0107019_A1	107	ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION	AMYLIN PHARMACEUTICALS INC; AMYLIN PHARMACEUTICALS LLC	77.5%	67.8	True	40
US_2015_0133373_A1	107	TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES	AMYLIN PHARMACEUTICALS INC; ASTRAZENECA PHARMACEUTICALS LP; AMYLIN PHARMACEUTICALS LLC	77.5%	67.8	True	41

Details on Sequence Hits

1 - US_8673860_B2 - SEQ ID NO 1065

Patent Number [US 8673860 B2](#)
 SEQ ID NO [1,065](#)

Title	Extended recombinant polypeptides and compositions comprising same
Assignee	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC
Publication Date	2014-03-18
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	904aa
Local % Id	77.5%
Score (bits)	77
Alignment Length	40

2 - [US_8673860_B2](#) - SEQ ID NO 1050

Patent Number	US_8673860_B2
SEQ ID NO	1,050
Title	Extended recombinant polypeptides and compositions comprising same
Assignee	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC
Publication Date	2014-03-18
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	184aa
Local % Id	77.5%
Score (bits)	70.5
Alignment Length	40

3 - [US_8957021_B2](#) - SEQ ID NO 886

Patent Number	US_8957021_B2
SEQ ID NO	886
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	184aa
Local % Id	77.5%
Score (bits)	70.5
Alignment Length	40

4 - [US_8673860_B2](#) - SEQ ID NO 1051

Patent Number	US_8673860_B2
SEQ ID NO	1,051
Title	Extended recombinant polypeptides and compositions comprising same
Assignee	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC
Publication Date	2014-03-18
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	184aa
Local % Id	77.5%
Score (bits)	70.1
Alignment Length	40

5 - US_8957021_B2 - SEQ ID NO 882

Patent Number	US 8957021 B2
SEQ ID NO	882
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	184aa
Local % Id	77.5%
Score (bits)	70.1
Alignment Length	40

6 - US_8957021_B2 - SEQ ID NO 1162

Patent Number	US 8957021 B2
SEQ ID NO	1,162
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	234aa
Local % Id	77.5%
Score (bits)	70.5
Alignment Length	40

7 - US_8957021_B2 - SEQ ID NO 1164

Patent Number	US 8957021 B2
SEQ ID NO	1,164
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	234aa
Local % Id	77.5%
Score (bits)	70.5
Alignment Length	40

8 - US_8673860_B2 - SEQ ID NO 1060

Patent Number	US 8673860 B2
SEQ ID NO	1,060
Title	Extended recombinant polypeptides and compositions comprising same
Assignee	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC
Publication Date	2014-03-18
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	915aa

Local % Id	77.5%
Score (bits)	73.2
Alignment Length	40

9 - US_8957021_B2 - SEQ ID NO 898

Patent Number	US_8957021_B2
SEQ ID NO	898
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	915aa
Local % Id	77.5%
Score (bits)	73.2
Alignment Length	40

10 - US_8673860_B2 - SEQ ID NO 1054

Patent Number	US_8673860_B2
SEQ ID NO	1.054
Title	Extended recombinant polypeptides and compositions comprising same
Assignee	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC
Publication Date	2014-03-18
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	580aa
Local % Id	77.5%
Score (bits)	72.8
Alignment Length	40

11 - US_8673860_B2 - SEQ ID NO 1052

Patent Number	US_8673860_B2
SEQ ID NO	1.052
Title	Extended recombinant polypeptides and compositions comprising same
Assignee	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC
Publication Date	2014-03-18
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	328aa
Local % Id	77.5%
Score (bits)	71.2
Alignment Length	40

12 - US_8957021_B2 - SEQ ID NO 884

Patent Number	US_8957021_B2
SEQ ID NO	884
Title	Glucose-regulating polypeptides and methods of making and using same

Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	True
Hit Sequence Length	328aa
Local % Id	77.5%
Score (bits)	71.2
Alignment Length	40

13 - [US_8673860_B2](#) - SEQ ID NO 1061

Patent Number	US_8673860_B2
SEQ ID NO	1,061
Title	Extended recombinant polypeptides and compositions comprising same
Assignee	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC
Publication Date	2014-03-18
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	904aa
Local % Id	77.5%
Score (bits)	73.2
Alignment Length	40

14 - [US_8957021_B2](#) - SEQ ID NO 900

Patent Number	US_8957021_B2
SEQ ID NO	900
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	904aa
Local % Id	77.5%
Score (bits)	73.2
Alignment Length	40

15 - [US_8957021_B2](#) - SEQ ID NO 892

Patent Number	US_8957021_B2
SEQ ID NO	892
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	617aa
Local % Id	77.5%
Score (bits)	72.8
Alignment Length	40

16 - US_8957021_B2 - SEQ ID NO 1178

Patent Number	US 8957021 B2
SEQ ID NO	1,178
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	1,060aa
Local % Id	77.5%
Score (bits)	73.6
Alignment Length	40

17 - US_8673860_B2 - SEQ ID NO 1057

Patent Number	US 8673860 B2
SEQ ID NO	1,057
Title	Extended recombinant polypeptides and compositions comprising same
Assignee	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC
Publication Date	2014-03-18
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	616aa
Local % Id	77.5%
Score (bits)	72.8
Alignment Length	40

18 - US_2014_0107019_A1 - SEQ ID NO 71

Patent Number	US 2014 0107019 A1
SEQ ID NO	71
Title	ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION
Assignee	AMYLIN PHARMACEUTICALS INC; AMYLIN PHARMACEUTICALS LLC
Publication Date	2014-04-17
Priority Date	2010-09-28
Ref. In Claims	True
Hit Sequence Length	93aa
Local % Id	77.5%
Score (bits)	68.6
Alignment Length	40

19 - US_2015_0133373_A1 - SEQ ID NO 71

Patent Number	US 2015 0133373 A1
SEQ ID NO	71
Title	TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES
Assignee	AMYLIN PHARMACEUTICALS INC; ASTRAZENECA PHARMACEUTICALS LP; AMYLIN PHARMACEUTICALS LLC
Publication Date	2015-05-14
Priority Date	2012-03-28
Ref. In Claims	True

Hit Sequence Length	93aa
Local % Id	77.5%
Score (bits)	68.6
Alignment Length	40

20 - [WO_2012_050923_A2](#) - SEQ ID NO 71

Patent Number	WO_2012_050923_A2
SEQ ID NO	71
Title	ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION
Assignee	
Publication Date	2012-04-19
Priority Date	2010-09-28
Ref. In Claims	True
Hit Sequence Length	93aa
Local % Id	77.5%
Score (bits)	68.6
Alignment Length	40

21 - [WO_2013_148966_A1](#) - SEQ ID NO 71

Patent Number	WO_2013_148966_A1
SEQ ID NO	71
Title	TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES
Assignee	
Publication Date	2013-10-03
Priority Date	2012-03-28
Ref. In Claims	True
Hit Sequence Length	93aa
Local % Id	77.5%
Score (bits)	68.6
Alignment Length	40

22 - [US_9089538_B2](#) - SEQ ID NO 10

Patent Number	US_9089538_B2
SEQ ID NO	10
Title	Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
Assignee	ZEALAND PHARMA A/S
Publication Date	2015-07-28
Priority Date	2010-04-27
Ref. In Claims	
Hit Sequence Length	45aa
Local % Id	77.5%
Score (bits)	67.4
Alignment Length	40

23 - [US_8957021_B2](#) - SEQ ID NO 1204

Patent Number	US_8957021_B2
SEQ ID NO	1,204

Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	1,204aa
Local % Id	77.5%
Score (bits)	73.2
Alignment Length	40

24 - US_8957021_B2 - SEQ ID NO 1170

Patent Number	US_8957021_B2
SEQ ID NO	1,170
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	761aa
Local % Id	77.5%
Score (bits)	73.2
Alignment Length	40

25 - US_8957021_B2 - SEQ ID NO 1180

Patent Number	US_8957021_B2
SEQ ID NO	1,180
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	1,049aa
Local % Id	77.5%
Score (bits)	73.2
Alignment Length	40

26 - US_8957021_B2 - SEQ ID NO 1196

Patent Number	US_8957021_B2
SEQ ID NO	1,196
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	905aa
Local % Id	77.5%
Score (bits)	73.2
Alignment Length	40

27 - US_8957021_B2 - SEQ ID NO 1206

Patent Number	US 8957021 B2
SEQ ID NO	1,206
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	1,193aa
Local % Id	77.5%
Score (bits)	73.2
Alignment Length	40

28 - US_2014_0107019_A1 - SEQ ID NO 55

Patent Number	US 2014 0107019 A1
SEQ ID NO	55
Title	ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION
Assignee	AMYLIN PHARMACEUTICALS INC; AMYLIN PHARMACEUTICALS LLC
Publication Date	2014-04-17
Priority Date	2010-09-28
Ref. In Claims	True
Hit Sequence Length	93aa
Local % Id	77.5%
Score (bits)	68.2
Alignment Length	40

29 - US_2015_0133373_A1 - SEQ ID NO 55

Patent Number	US 2015 0133373 A1
SEQ ID NO	55
Title	TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES
Assignee	AMYLIN PHARMACEUTICALS INC; ASTRAZENECA PHARMACEUTICALS LP; AMYLIN PHARMACEUTICALS LLC
Publication Date	2015-05-14
Priority Date	2012-03-28
Ref. In Claims	True
Hit Sequence Length	93aa
Local % Id	77.5%
Score (bits)	68.2
Alignment Length	40

30 - WO_2012_050923_A2 - SEQ ID NO 55

Patent Number	WO 2012 050923 A2
SEQ ID NO	55
Title	ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION
Assignee	
Publication Date	2012-04-19
Priority Date	2010-09-28
Ref. In Claims	True

Hit Sequence Length	93aa
Local % Id	77.5%
Score (bits)	68.2
Alignment Length	40

31 - WO_2013_148966_A1 - SEQ ID NO 55

Patent Number	WO_2013_148966_A1
SEQ ID NO	55
Title	TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES
Assignee	
Publication Date	2013-10-03
Priority Date	2012-03-28
Ref. In Claims	True
Hit Sequence Length	93aa
Local % Id	77.5%
Score (bits)	68.2
Alignment Length	40

32 - US_8673860_B2 - SEQ ID NO 1053

Patent Number	US_8673860_B2
SEQ ID NO	1,053
Title	Extended recombinant polypeptides and compositions comprising same
Assignee	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC
Publication Date	2014-03-18
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	544aa
Local % Id	77.5%
Score (bits)	72.4
Alignment Length	40

33 - US_8673860_B2 - SEQ ID NO 1062

Patent Number	US_8673860_B2
SEQ ID NO	1,062
Title	Extended recombinant polypeptides and compositions comprising same
Assignee	AMUNIX INC; AMUNIX OPERATING INC; AMUNIX PHARMACEUTICALS INC
Publication Date	2014-03-18
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	915aa
Local % Id	77.5%
Score (bits)	72.8
Alignment Length	40

34 - US_8957021_B2 - SEQ ID NO 902

Patent Number	US_8957021_B2
SEQ ID NO	902

Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	915aa
Local % Id	77.5%
Score (bits)	72.8
Alignment Length	40

35 - US_8957021_B2 - SEQ ID NO 1182

Patent Number	US_8957021_B2
SEQ ID NO	1,182
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	1,060aa
Local % Id	77.5%
Score (bits)	72.8
Alignment Length	40

36 - US_8957021_B2 - SEQ ID NO 1190

Patent Number	US_8957021_B2
SEQ ID NO	1,190
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	378aa
Local % Id	77.5%
Score (bits)	71.6
Alignment Length	40

37 - US_8957021_B2 - SEQ ID NO 1208

Patent Number	US_8957021_B2
SEQ ID NO	1,208
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	1,204aa
Local % Id	77.5%
Score (bits)	73.2
Alignment Length	40

38 - US_8957021_B2 - SEQ ID NO 1188

Patent Number	US 8957021 B2
SEQ ID NO	1,188
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	378aa
Local % Id	77.5%
Score (bits)	71.6
Alignment Length	40

39 - US_8957021_B2 - SEQ ID NO 1202

Patent Number	US 8957021 B2
SEQ ID NO	1,202
Title	Glucose-regulating polypeptides and methods of making and using same
Assignee	AMUNIX INC; AMUNIX OPERATING INC
Publication Date	2015-02-17
Priority Date	2009-02-03
Ref. In Claims	
Hit Sequence Length	1,193aa
Local % Id	77.5%
Score (bits)	72.8
Alignment Length	40

40 - US_2014_0107019_A1 - SEQ ID NO 107

Patent Number	US 2014 0107019 A1
SEQ ID NO	107
Title	ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION
Assignee	AMYLIN PHARMACEUTICALS INC; AMYLIN PHARMACEUTICALS LLC
Publication Date	2014-04-17
Priority Date	2010-09-28
Ref. In Claims	True
Hit Sequence Length	88aa
Local % Id	77.5%
Score (bits)	67.8
Alignment Length	40

41 - US_2015_0133373_A1 - SEQ ID NO 107

Patent Number	US 2015 0133373 A1
SEQ ID NO	107
Title	TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES
Assignee	AMYLIN PHARMACEUTICALS INC; ASTRAZENECA PHARMACEUTICALS LP; AMYLIN PHARMACEUTICALS LLC
Publication Date	2015-05-14
Priority Date	2012-03-28
Ref. In Claims	True

Hit Sequence Length	88aa
Local % Id	77.5%
Score (bits)	67.8
Alignment Length	40

* * * * * Welcome to STN International * * * * *

NEWS 1 DEC 20 2019 MeSH Version Now Available in MEDLINE on STN
NEWS 2 JAN 4 DWPI Manual Code revision in 2019
NEWS 3 JAN 29 The 2019 Version of MEDLINE Now Available on STN(TM)
NEWS 4 FEB 4 INPADOC/INPAFAM: Major enhancements for PCT
NEWS 5 FEB 26 FRFULL and GBFULL reloaded
NEWS 6 MAR 7 Search Limits Significantly Expanded Exclusively in STNext(R)
NEWS 7 MAR 7 New Key Terms field supports efficient full-text searching
and results evaluation in Patent Full-text Databases
NEWS 8 MAR 8 CPC Combination Sets Now Fully Available in Derwent
World Patents Index
NEWS 9 MAR 25 Derwent World Patent Index Coverage Expanded to Include
Eight Former Soviet Republics and the Eurasian Patent
Organization (EAPO)
NEWS 10 APR 3 Derwent World Patents Index and Derwent Markush
Resource (DWPIIM) Now Updated Twice Weekly
NEWS 11 APR 11 Updates in database World Surface Coatings Abstracts
(file WSCA) have resumed
NEWS 12 APR 18 New legal status codes for US patent applications and
granted patents in INPADOC
NEWS 13 APR 30 Derwent Markush Resource (DWPIIM) Database Enhancements
NEWS 14 MAY 28 Second 2019 update to Emtree(TM) now available on STN(R)

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS TRAINING Find instructor-led and self-directed training opportunities

Enter NEWS followed by the item number or name to see news on that
specific topic.

For pricing information enter HELP PRICE or HELP COST at any arrow prompt.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

Access the latest version of STN.

Log into STNext with your STN login ID at <https://www.stn.org>

STNext is updated frequently. To see the latest STNext Release Notes, click

<https://www.stn.org/help/stnext/ReleaseNotes.htm>

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:11:04 ON 26 AUG 2019

=> Fil CAPLUS REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.46	0.46

FILE 'CAPLUS' ENTERED AT 11:12:43 ON 26 AUG 2019
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
COPYRIGHT (C) 2019 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'REGISTRY' ENTERED AT 11:12:43 ON 26 AUG 2019
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
COPYRIGHT (C) 2019 American Chemical Society (ACS)

=> S conjugates and glucagon and glp-1 and gip and formula and pd<20151231


L1 1 FILE CAPLUS
L2 0 FILE REGISTRY

TOTAL FOR ALL FILES

L3 1 CONJUGATES AND GLUCAGON AND GLP-1 AND GIP AND FORMULA AND PD<201
51231

=> D L3 1 abs bib hit

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2019 ACS on STN
GI



AB Provided herein are **glucagon** superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compns. and kits of the **conjugates** of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the **conjugates** of the invention. The **glucagon** superfamily peptide **conjugates** of the invention can be represented by the following **formula**: Q-L-Y wherein Q is a **glucagon** superfamily peptide, Y is a GR ligand, and L is a linking group or a bond. The **glucagon** superfamily peptide (Q) in some embodiments can be a **glucagon** related peptide that exhibits agonist activity at the **glucagon** receptor, agonist activity at the **GLP-1** receptor, agonist activity at the **GIP** receptor, co-agonist activity at the **glucagon** and **GLP-1** receptors, co-agonist activity at the **glucagon** and **GIP** receptors, co-agonist activity at the **GLP-1** and **GIP** receptors, or triagonist activity at the **glucagon**, **GIP**, and **GLP-1** receptors. In some embodiments, the **glucagon** related peptide exhibits antagonist activity at the **glucagon**, **GLP-1** or **GIP** receptor.

[PatentPak PDF](#)

AN 2013:796014 CAPLUS [Full-text](#)

DN 159:36059

TI **Glucagon** superfamily peptides exhibiting glucocorticoid receptor activity

IN Dimarchi, Richard D.; Yang, Bin

PA Indiana University Research and Technology Corporation, USA

SO PCT Int. Appl., 420pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1
PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2013074910	A1	20130523	English	PDF
US 20130157934	A1	20130620	English	PDF
US 8859491	B2	20141014	English	PDF
CN 103957927	A	20140730	Chinese	PDF
CN 103957927	B	20161109	Chinese	PDF
KR 2014097151	A	20140806	Korean	PDF
EP 2780031	B1	20180307	English	PDF
JP 2015504431	T	20150212	Japanese	PDF
JP 6324315	B2	20180516	Japanese	PDF
ES 2672880	T3	20180618	Spanish	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2013074910	A1	20130523	WO 2012-US65492	20121116
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM				
CA 2847246	A1	20130523	CA 2012-2847246	20121116
US 20130157934	A1	20130620	US 2012-13679121	20121116
US 8859491	B2	20141014		
CN 103957927	A	20140730	CN 2012-80049164	20121116
CN 103957927	B	20161109		
KR 2014097151	A	20140806	KR 2014-7012192	20121116
EP 2780031	A1	20140924	EP 2012-849285	20121116
EP 2780031	B1	20180307		
R: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR				
JP 2015504431	T	20150212	JP 2014-542489	20121116
JP 6324315	B2	20180516		
BR 112014007124	A2	20170613	BR 2014-112014007124	20121116
ES 2672880	T3	20180618	ES 2012-849285	20121116
MX 2014003579	A	20150410	MX 2014-3579	20140325
IN 2014DN03510	A	20160520	IN 2014-DN3510	20140501
PRAI US 2011-61561094	P	20111117		
WO 2012-US65492	W	20121116		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 159:36059; MARPAT 159:36059

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI **Glucagon** superfamily peptides exhibiting glucocorticoid receptor activity

PI WO 2013074910 A1 **20130523**

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2013074910	A1	20130523	WO 2012-US65492	20121116
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,				

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM

CA 2847246	A1	20130523	CA 2012-2847246	20121116
US 20130157934	A1	20130620	US 2012-13679121	20121116
US 8859491	B2	20141014		
CN 103957927	A	20140730	CN 2012-80049164	20121116
CN 103957927	B	20161109		
KR 2014097151	A	20140806	KR 2014-7012192	20121116
EP 2780031	A1	20140924	EP 2012-849285	20121116
EP 2780031	B1	20180307		
R: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR				
JP 2015504431	T	20150212	JP 2014-542489	20121116
JP 6324315	B2	20180516		
BR 112014007124	A2	20170613	BR 2014-112014007124	20121116
ES 2672880	T3	20180618	ES 2012-849285	20121116
MX 2014003579	A	20150410	MX 2014-3579	20140325
IN 2014DN03510	A	20160520	IN 2014-DN3510	20140501

AB Provided herein are **glucagon** superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compns. and kits of the **conjugates** of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the **conjugates** of the invention. The **glucagon** superfamily peptide **conjugates** of the invention can be represented by the following **formula**: Q-L-Y wherein Q is a **glucagon** superfamily peptide, Y is a GR ligand, and L is a linking group or a bond. The **glucagon** superfamily peptide (Q) in some embodiments can be a **glucagon** related peptide that exhibits agonist activity at the **glucagon** receptor, agonist activity at the **GLP-1** receptor, agonist activity at the **GIP** receptor, co-agonist activity at the **glucagon** and **GLP-1** receptors, co-agonist activity at the **glucagon** and **GIP** receptors, co-agonist activity at the **GLP-1** and **GIP** receptors, or triagonist activity at the **glucagon**, **GIP**, and **GLP-1** receptors. In some embodiments, the **glucagon** related peptide exhibits antagonist activity at the **glucagon**, **GLP-1** or **GIP** receptor.

ST **glucagon** superfamily peptide conjugate glucocorticoid receptor ligand prepn; antidiabetic antiobesity **glucagon** superfamily peptide conjugate glucocorticoid

IT Estrogen receptor a
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (binding; prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT Peptides
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (**conjugates**; prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT Ligands
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (glucocorticoid receptor, peptide comprising; prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid

receptor activity)

IT Glucocorticoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ligands; prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT Linking agents
(peptide comprising; prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT Disulfide group
(peptide linker comprising; prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT Amides
Esters
Ethers
Hydrazones
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(peptide linker comprising; prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT Acylation
Adipose tissue
Antidiabetic agents
Antiobesity agents
Appetite
Body weight
Combination chemotherapy
Diabetes mellitus
Drug delivery systems
Drug targets
Fatty liver disease
Hepatoprotective agents
Human
Metabolic syndrome X
Nervous system agents
Neurodegenerative disease
Obesity
PEGylation
Pharmacokinetics
Prodrugs
Protein sequences
(prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT Dimers
Glucagon receptors
Glucagon-like peptide-1 receptors
Glucose-dependent insulinotropic polypeptide receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT Solid phase synthesis
(solid-phase peptide synthesis; prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT Liver
Uterus
(wt.; prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT 9004-08-4, Cathepsin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(-cleavable moiety, peptide linker comprising; prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT 16941-32-5P, **Glucagon** (swine) 40077-57-4P, Vasoactive intestinal octacosapeptide (swine) 87403-73-4P 90830-28-7P, 1-29-Somatoliberein (human pancreatic islet) 106612-94-6P, 7-37-**Glucagon**-like peptide I (human) 107444-51-9P 108153-74-8P 110084-95-2P 110121-11-4P 118934-21-7P 121378-88-9P 123475-27-4P 133920-04-4P 134000-89-8P 251987-23-2P 774592-53-9P 863989-03-1P 870249-65-3P 916897-07-9P 936920-97-7P 936920-98-8DP, butyrolactone **conjugates** 936920-99-9DP, butyrolactone **conjugates** 936921-06-1P 936921-07-2P 1037751-81-7P 1037751-82-8P 1037751-83-9P 1048948-37-3P 1048948-38-4P 1048948-39-5P 1048948-40-8P 1048948-41-9P 1048948-43-1P 1048948-46-4P 1048948-48-6P 1048948-49-7P 1048948-50-0P 1048948-51-1P

1048948-52-2P	1048948-53-3P	1048948-54-4P	1048948-55-5P
1048948-56-6P	1048948-57-7P	1048948-58-8P	1048948-59-9P
1048948-60-2P	1048948-61-3P	1048948-62-4P	1048948-63-5P
1048948-64-6P	1048948-66-8P	1048948-67-9P	1048948-68-0P
1048948-69-1P	1048948-70-4P	1048948-71-5P	1048948-72-6P
1048948-73-7P	1048948-74-8P	1048948-75-9P	1048948-77-1P
1048948-78-2P	1048948-79-3P	1048948-80-6P	1048948-81-7P
1048948-82-8P	1048948-84-0P	1048948-85-1P	1048948-86-2P
1048948-87-3P	1048948-88-4P	1048948-89-5P	1048948-90-8P
1048948-91-9P	1048948-92-0P	1048948-93-1P	1048948-94-2P
1048948-95-3P	1048948-96-4P	1048948-97-5P	1048948-98-6P
1048948-99-7P	1048949-00-3P	1048949-01-4P	1048949-02-5P
1048949-03-6P	1048949-04-7P	1048949-05-8P	1048949-06-9P
1048949-07-0P	1048949-08-1P	1048949-09-2P	1048949-10-5P
1048949-11-6P	1048949-12-7P	1048949-13-8P	1048949-14-9P
1048949-15-0P	1048949-16-1P	1048949-17-2P	1048949-18-3P
1048949-19-4P	1048949-20-7P	1048949-21-8P	1048949-22-9P
1048949-23-0P	1048949-24-1P	1048949-25-2P	1048949-26-3P
1048949-27-4P	1048949-28-5P	1048949-29-6P	1048949-30-9P
1048949-31-0P	1048949-32-1P	1048949-33-2P	1048949-34-3P
1048949-35-4P	1048949-36-5P	1048949-37-6P	1048949-38-7P
1048949-39-8P	1048949-40-1P	1048949-41-2P	1048949-42-3P
1048949-43-4P	1048949-44-5P	1048949-45-6P	1048949-46-7P
1048949-47-8P	1048949-48-9P	1048949-49-0P	1048949-50-3P
1048949-52-5P	1048949-54-7P	1048949-56-9P	1048949-58-1P
1048949-59-2P	1048949-60-5P	1048949-61-6P	1048949-62-7P
1048949-63-8P	1048949-64-9P	1048949-65-0P	1048949-66-1P
1048949-67-2P	1048949-68-3P	1048949-69-4P	1048949-70-7P
1048949-71-8P	1048949-72-9P	1048949-73-0P	1048949-74-1P
1048949-75-2P	1048949-77-4P	1048949-78-5P	1048949-79-6P
1048949-80-9P	1048949-81-0P	1048949-82-1P	1048949-83-2P
1048949-84-3P	1048949-86-5P	1048949-88-7P	1048949-89-8DP, PEGylated
1048949-90-1DP, PEGylated	1048949-91-2DP, PEGylated	1048949-92-3DP, PEGylated	1048949-93-4DP, PEGylated
1048949-96-7DP, PEGylated	1048949-97-8DP, PEGylated	1048949-98-9DP, PEGylated	1048949-99-0DP, PEGylated
1048950-01-1DP, PEGylated	1048950-02-2DP, PEGylated	1048950-03-3DP, PEGylated	1048950-04-4DP, PEGylated
1048950-06-6DP, PEGylated	1048950-07-7DP, PEGylated	1048950-08-8DP, PEGylated	1048950-10-2DP, PEGylated
1048950-12-4DP, PEGylated	1048950-13-5DP, PEGylated	1048950-14-6DP, PEGylated	1048950-15-7DP, PEGylated
1048950-17-9DP, PEGylated	1048950-18-0DP, PEGylated	1048950-19-1DP, PEGylated	1048950-20-4DP, PEGylated
1048950-22-6DP, PEGylated	1048950-23-7DP, PEGylated	1048950-24-8DP, PEGylated	1048950-25-9DP, PEGylated
1048950-27-1DP, PEGylated	1048950-28-2DP, PEGylated	1048950-29-3DP, PEGylated	1048950-30-6DP, PEGylated
1048950-32-8DP, PEGylated	1048950-34-0DP, PEGylated	1048950-36-2DP, PEGylated	1048950-37-3DP, PEGylated
1048950-39-5DP, PEGylated	1048950-40-8DP, PEGylated	1048950-41-9DP, PEGylated	1048950-42-0DP, PEGylated
1048950-44-2DP, PEGylated	1048950-45-3DP, PEGylated	1048950-46-4DP, PEGylated	1048950-47-5DP, PEGylated
1048950-49-7DP, PEGylated	1048950-50-0DP, PEGylated	1048950-51-1DP, PEGylated	1048950-52-2DP, PEGylated
1048950-54-4DP, PEGylated	1048950-55-5DP, PEGylated	1048950-56-6DP, PEGylated	1048950-57-7DP, PEGylated
1048950-58-8DP, PEGylated	1048950-60-2DP, PEGylated	1048950-61-3DP, PEGylated	1048950-62-4DP, PEGylated
1048950-64-6DP, PEGylated	1048950-65-7DP, PEGylated	1048950-66-8DP, PEGylated	1048950-67-9DP, PEGylated
1048950-69-1DP, PEGylated	1048950-70-4DP, PEGylated	1048950-71-5DP, PEGylated	1048950-72-6DP, PEGylated
1048950-74-8DP, PEGylated	1048950-75-9DP, PEGylated	1048950-76-0DP, PEGylated	

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence, fusion peptide comprising; prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT	1048950-59-9DP, PEGylated	1048950-60-2DP, PEGylated	1048950-61-3DP, PEGylated
	1048950-62-4DP, PEGylated	1048950-63-5DP, PEGylated	1048950-64-6DP, PEGylated
	1048950-67-9DP, PEGylated	1048950-68-0DP, PEGylated	1048950-69-1DP, PEGylated
	1048950-70-4DP, PEGylated	1048950-71-5DP, PEGylated	1048950-72-6DP, PEGylated
	1048950-73-7DP, PEGylated	1048950-74-8DP, PEGylated	1048950-75-9DP, PEGylated
	1048950-76-0DP, PEGylated		

PEGylated 1048950-77-1DP, PEGylated 1048950-78-2DP, PEGylated 1048950-79-3DP, PEGylated 1048950-80-6DP, PEGylated 1048950-81-7DP,
 PEGylated 1048950-82-8DP, PEGylated 1048950-83-9DP, PEGylated 1048950-84-0DP, PEGylated 1048950-91-9DP, PEGylated 1048950-92-0DP,
 PEGylated 1048950-93-1DP, PEGylated 1048950-94-2DP, PEGylated 1048950-95-3DP, PEGylated 1048950-96-4DP, PEGylated 1048950-97-5DP,
 PEGylated 1048950-99-7DP, PEGylated 1048951-01-4DP, PEGylated 1048951-02-5DP, PEGylated 1048951-03-6DP, PEGylated 1048951-04-7DP,
 PEGylated 1048951-05-8DP, PEGylated 1048951-06-9DP, PEGylated 1048951-07-0DP, PEGylated 1048951-08-1DP, PEGylated 1048951-09-2DP,
 PEGylated 1048951-10-5DP, PEGylated 1048951-11-6DP, PEGylated 1048951-12-7DP, PEGylated 1048951-13-8DP, PEGylated 1048951-14-9DP,
 PEGylated 1048951-15-0DP, PEGylated 1048951-16-1DP, PEGylated 1048951-17-2DP, PEGylated 1048951-18-3DP, PEGylated 1048951-19-4DP,
 PEGylated 1048951-20-7DP, PEGylated 1048951-21-8DP, PEGylated 1048951-22-9DP, PEGylated 1048951-23-0DP, PEGylated 1048951-24-1DP,
 PEGylated 1048951-25-2DP, PEGylated 1048951-26-3DP, PEGylated 1048951-27-4DP, PEGylated 1048951-28-5DP, PEGylated 1048951-29-6DP,
 PEGylated 1048951-30-9DP, PEGylated 1048951-31-0DP, PEGylated 1048951-32-1DP, PEGylated 1048951-33-2DP, PEGylated 1048951-34-3DP,
 PEGylated 1048951-36-5DP, PEGylated 1048951-37-6DP, PEGylated 1048951-38-7DP, PEGylated 1048951-39-8DP, PEGylated 1048951-40-1DP,
 PEGylated 1048951-41-2DP, PEGylated 1048951-42-3DP, PEGylated 1048951-43-4DP, PEGylated 1048951-44-5DP, PEGylated 1048951-45-6DP,
 PEGylated 1048951-46-7DP, PEGylated 1048951-47-8DP, PEGylated 1048951-48-9DP, PEGylated 1048951-49-0DP, PEGylated 1048951-50-3DP,
 PEGylated 1048951-55-8DP, PEGylated 1048951-56-9DP, PEGylated 1048951-57-0DP, PEGylated 1048951-58-1P 1048951-59-2P 1048951-60-5P
 1048951-61-6P 1048951-62-7P 1048951-64-9P 1048951-65-0P
 1048951-66-1P 1048951-67-2P 1048951-68-3P 1048951-69-4P
 1048951-70-7P 1048951-71-8P 1048951-72-9P 1048951-73-0P
 1048951-74-1P 1048951-75-2P 1048951-77-4P 1048951-78-5P
 1048951-79-6P 1048951-82-1P 1048951-83-2P 1048951-84-3P
 1048951-85-4P 1048951-86-5P 1048951-87-6P 1048951-88-7P
 1048951-89-8P 1048951-90-1P 1048951-91-2P 1048951-92-3P
 1048951-93-4P 1048951-94-5P 1048951-95-6P 1048951-96-7P
 1048951-97-8P 1048951-98-9P 1048951-99-0P 1048952-00-6P
 1048952-01-7P 1048952-02-8P 1048952-03-9P 1048952-04-0P
 1048952-05-1P 1048952-06-2P 1048952-07-3P 1048952-08-4P
 1048952-09-5P 1048952-10-8P 1048952-11-9P 1048952-12-0P
 1048952-13-1P 1048952-14-2P 1048952-15-3P 1048952-16-4P
 1048952-17-5P 1048952-18-6P 1048952-19-7P 1048952-20-0P
 1048952-21-1P 1048952-22-2P 1048952-23-3P 1048952-24-4P
 1048952-25-5P 1048952-26-6P 1048952-27-7P 1048952-28-8P
 1048952-29-9P 1048952-30-2P 1048952-31-3P 1048952-32-4P
 1048952-33-5P 1048952-34-6P 1048952-35-7P 1048952-36-8P
 1048952-37-9P 1048952-38-0P 1048952-39-1P 1048952-40-4P
 1048952-41-5P 1048952-42-6P 1048952-43-7P 1048952-44-8P
 1048952-45-9P 1048952-46-0P 1048952-47-1P 1048952-48-2P
 1048952-49-3P 1048952-50-6P 1048952-51-7P 1048952-52-8P
 1048952-53-9P 1048952-54-0P 1048952-55-1P 1048952-56-2P
 1048952-57-3P 1048952-58-4P 1048952-59-5P 1048952-60-8P
 1048952-61-9P 1048952-62-0P 1048952-63-1P 1048952-64-2P
 1048952-65-3P 1048952-66-4P 1048952-67-5P 1048952-68-6P
 1048952-70-0DP, PEGylated 1048952-71-1DP, PEGylated 1048952-72-2DP,
 PEGylated 1048952-95-9P 1048955-08-3P 1048955-09-4P
 1048955-10-7DP, PEGylated 1150584-46-5P 1150584-47-6P 1150584-49-8P
 1150584-63-6P 1150584-64-7P 1150584-65-8P 1150584-66-9P
 1150584-67-0P 1150584-68-1P 1150584-73-8P 1150584-77-2P
 1150584-79-4P 1150584-81-8P 1150584-83-0P 1150584-84-1DP, PEGylated
 1150584-93-2P 1150584-95-4P 1150584-96-5P 1150585-02-6P
 1150585-05-9P 1150585-07-1DP, C16 acylated 1150585-08-2P
 1150585-11-7P 1180012-62-7P 1181207-50-0P 1181207-51-1P
 1181207-61-3P 1181207-64-6P 1181207-65-7P 1181207-67-9P
 1181207-88-4P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP
 (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (amino acid sequence, fusion peptide comprising; prepn. and activity of
 glucagon superfamily peptides exhibiting glucocorticoid
 receptor activity)

IT 1184663-12-4P 1202051-27-1P 1202051-28-2P 1202051-29-3P

1202051-30-6P 1202051-32-8P 1202051-33-9P 1202051-34-0P
1202051-35-1P 1202051-36-2P 1202051-37-3P 1202051-39-5P
1202051-40-8P 1202051-41-9P 1202051-42-0P 1202051-43-1P
1202051-45-3P 1202051-46-4P 1202051-47-5P 1202051-48-6P
1202051-49-7P 1202051-50-0P 1202051-51-1P 1202051-52-2P
1202051-62-4P 1202171-92-3P 1206832-07-6P 1206832-08-7P
1206832-09-8P 1206832-10-1P 1206832-12-3P 1206832-13-4P
1206832-14-5P 1206832-15-6P 1206832-16-7P 1206832-17-8P
1206832-18-9P 1206832-19-0P 1206832-20-3P 1206832-21-4P
1206832-22-5P 1206832-25-8P 1206832-26-9P 1206832-27-0P
1206832-28-1P 1206832-29-2P 1206832-30-5P 1206832-33-8P
1206832-34-9DP, PEGylated 1206832-35-0P 1206832-36-1P 1206832-37-2P
1206832-38-3P 1206832-39-4P 1206832-40-7P 1206832-41-8P
1206832-42-9P 1206832-43-0P 1206832-44-1P 1206832-45-2P
1206832-46-3DP, PEGylated 1206832-48-5P 1233138-68-5P 1233139-24-6P
1233141-02-0DP, PEGylated 1233141-03-1DP, PEGylated 1233141-04-2DP,
PEGylated 1233141-06-4DP, PEGylated 1233141-07-5DP, PEGylated
1233141-09-7DP, PEGylated 1233141-72-4DP, PEGylated 1233141-80-4P
1233142-65-8DP, PEGylated 1233142-76-1DP, PEGylated 1233142-79-4DP,
PEGylated 1233142-93-2DP, PEGylated 1233142-96-5DP, PEGylated
1233143-03-7DP, PEGylated 1233143-05-9DP, PEGylated 1233143-08-2DP,
PEGylated 1233143-20-8P 1233143-23-1P 1233143-24-2P 1233143-26-4P
1233143-29-7P 1233143-31-1DP, PEGylated 1233143-36-6P
1233143-68-4DP, PEGylated C16-Trp conjugate 1233143-78-6P
1233143-87-7DP, C16-dipeptide **conjugates** 1233143-89-9DP, C16
acylated 1233143-91-3DP, C16-dipeptide **conjugates**
1233143-94-6DP, C16 acylated 1233143-96-8DP, C16 acylated
1233143-97-9DP, C16 acylated 1233143-99-1DP, C16-dipeptide
conjugates 1233144-07-4P 1233144-15-4P 1233144-17-6P
1233144-20-1DP, PEGylated 1233144-30-3P 1233144-43-8DP, PEGylated
1233144-49-4P 1233144-99-4P 1233145-01-1P 1233145-04-4P
1233145-07-7P 1233145-09-9P 1233145-11-3P 1233145-13-5P
1233145-16-8P 1233145-71-5P 1233146-11-6P 1233146-15-0P
1233146-33-2P 1233146-35-4P 1233146-39-8P 1233146-40-1P
1233146-44-5P 1233146-46-7P 1233146-47-8P 1233146-48-9P
1233146-49-0P 1233146-53-6P 1233146-54-7P 1233146-55-8P
1233146-56-9P 1233146-59-2DP, C16 acylated 1233146-60-5DP,
C16-dipeptide **conjugates** 1233146-61-6DP, C16-dipeptide
conjugates 1233146-62-7DP, C16-dipeptide **conjugates**
1233146-63-8DP, C16-dipeptide **conjugates** 1233146-64-9DP, C16
acylated 1233146-66-1DP, C16-dipeptide **conjugates**
1233146-67-2DP, C16-dipeptide **conjugates** 1233146-68-3DP,
PEGylated 1233146-69-4P 1233146-70-7DP, PEGylated 1233146-71-8P
1233146-72-9DP, C16 acylated 1233146-73-0DP, PEGylated 1233146-74-1DP,
PEGylated 1233146-75-2P 1233146-76-3P 1233146-77-4DP, C16 acylated
1233146-78-5DP, PEGylated C16 derivs. 1233146-79-6DP, PEGylated C16
derivs. 1233146-80-9DP, PEGylated C16 derivs. 1233146-81-0DP, C16
acylated 1233146-82-1DP, C16 acylated 1233146-83-2DP, PEGylated C16
conjugates 1233146-85-4DP, C16 acylated 1259369-96-4DP,
PEGylated 1312034-61-9P 1350306-24-9P 1350306-25-0P 1350306-26-1P
1350306-27-2P 1350306-28-3P 1350306-29-4P 1350306-60-3P
1350306-64-7P 1352810-83-3DP, C16 acylated 1438895-71-6P
1438896-33-3DP, PEGylated 1438896-60-6P 1438896-66-2P
1438896-67-3DP, PEGylated 1438896-68-4DP, C18-Trp conjugate
1438896-69-5DP, PEGylated C16-Trp conjugate 1438896-70-8DP, PEGylated
C16-Glu conjugate 1438896-71-9DP, PEGylated C16-Trp conjugate
1438896-72-0P 1438896-73-1P 1438896-74-2DP, PEGylated
1438896-75-3DP, PEGylated 1438896-77-5DP, PEGylated 1438896-78-6P
1438896-79-7DP, C16 acylated 1438896-80-0DP, C16 acylated
1438896-81-1DP, C16 acylated 1438896-82-2DP, PEGylated C16
conjugates 1438896-83-3DP, PEGylated C16 **conjugates**
1438896-84-4DP, PEGylated C16 **conjugates** 1438896-87-7DP,
PEGylated 1438896-88-8DP, C16 acylated 1438896-89-9DP, butyrolactone
conjugates 1438896-90-2DP, PEGylated 1438896-91-3DP, PEGylated
1438896-94-6P 1438896-95-7P 1438896-96-8P 1438896-97-9P
1438896-98-0P 1438896-99-1P 1438897-00-7P 1438897-01-8P
1438897-02-9DP, C16 acylated 1438897-03-0DP, fragments and derivs.
1438897-05-2DP, PEGylated 1438897-06-3DP, PEGylated 1438897-07-4DP,
PEGylated 1438897-08-5DP, PEGylated 1438897-09-6DP, PEGylated
1438902-13-6P 1438902-14-7P 1438902-15-8P 1438902-16-9P
1438902-17-0P 1438902-18-1P 1438902-19-2P 1438902-20-5P
1438902-21-6P 1438902-22-7P 1438902-23-8P 1438902-24-9DP, PEGylated

1438902-25-ODP, PEGylated 1438902-26-1DP, PEGylated 1438902-27-2P
 1438902-28-3P 1438902-29-4P 1438902-30-7P 1438902-31-8P
 1438902-32-9P 1438902-33-0P 1438902-34-1P 1438902-35-2P
 1438902-36-3P 1438902-37-4P 1438902-38-5P 1438902-39-6P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP
 (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (amino acid sequence, fusion peptide comprising; prepn. and activity of
glucagon superfamily peptides exhibiting glucocorticoid
 receptor activity)

IT 1438902-40-9P 1438902-41-0P 1438902-42-1DP, PEGylated 1438902-43-2P
 1438902-44-3P 1438902-45-4P 1438902-46-5P 1438902-47-6P
 1438902-48-7DP, PEGylated 1438902-49-8DP, PEGylated 1438902-50-1DP,
 PEGylated 1438902-51-2DP, PEGylated 1438902-52-3DP, PEGylated
 1438902-53-4DP, PEGylated 1438902-54-5DP, PEGylated 1438902-55-6P
 1438902-56-7P 1438902-57-8P 1438902-58-9P 1438902-59-0P
 1438902-60-3P 1438902-61-4DP, PEGylated 1438902-62-5DP, PEGylated
 1438902-63-6P 1438902-64-7P 1438902-65-8P 1438902-66-9P
 1438902-67-0P 1438902-68-1P 1438902-69-2DP, acylated derivs.
 1438902-70-5DP, acylated derivs. 1438902-71-6P 1438902-72-7P
 1438902-74-9DP, PEGylated C16 **conjugates** 1438902-75-0P
 1438902-76-1P 1438902-77-2P 1438902-78-3P 1438902-79-4P
 1438902-80-7P 1438902-81-8P 1438902-82-9P 1438902-83-0P
 1438902-84-1DP, PEGylated 1438902-85-2DP, PEGylated 1438902-86-3DP,
 PEGylated 1438902-87-4DP, PEGylated 1438902-88-5DP, PEGylated
 1438902-89-6DP, PEGylated 1438902-90-9P 1438902-91-0P 1438902-92-1P
 1438902-93-2P 1438902-94-3P 1438902-95-4P 1438902-96-5P
 1438902-97-6P 1438902-98-7P 1438902-99-8P 1438903-00-4P
 1438903-01-5P 1438903-02-6P 1438903-03-7P 1438903-04-8P
 1438903-05-9P 1438903-06-0P 1438903-07-1P 1438903-08-2P
 1438903-09-3P 1438903-10-6P 1438903-11-7DP, PEGylated
 1438903-12-8DP, PEGylated 1438903-13-9DP, acylated derivs.
 1438903-14-0P 1438903-15-1P 1438903-16-2P 1438903-17-3P
 1438903-18-4P 1438903-19-5P 1438903-20-8P 1438903-21-9P
 1438903-22-0P 1438903-23-1P 1438903-24-2P 1438903-25-3P
 1438903-26-4P 1438903-27-5P 1438903-28-6P 1438903-29-7P
 1438903-30-0P 1438903-31-1P 1438903-32-2P 1438903-33-3P
 1438903-34-4P 1438903-35-5P 1438903-36-6P 1438903-37-7P
 1438903-38-8P 1438903-39-9P 1438903-40-2P 1438903-41-3P
 1438903-42-4P 1438903-43-5P 1438903-44-6P 1438903-45-7P
 1438903-46-8P 1438903-47-9P 1438903-48-0P 1438903-49-1P
 1438903-50-4P 1438903-51-5P 1438903-52-6P 1438903-53-7P
 1438903-54-8P 1438903-55-9P 1438903-56-0P 1438903-57-1P
 1438903-58-2P 1438903-59-3P 1438903-60-6P 1438903-61-7P
 1438903-62-8P 1438903-63-9P 1438903-64-0P 1438903-65-1P
 1438903-66-2P 1438903-67-3P 1438903-68-4P 1438903-69-5P
 1438903-70-8P 1438903-71-9P 1438903-72-0P 1438903-73-1P
 1438903-74-2P 1438903-75-3P 1438903-76-4P 1438903-77-5P
 1438903-78-6P 1438903-79-7P 1438903-80-0P 1438903-81-1P
 1438903-82-2P 1438903-83-3P 1438903-84-4P 1438903-85-5P
 1438903-86-6P 1438903-87-7P 1438903-88-8P 1438903-89-9P
 1438903-90-2P 1438903-91-3P 1438903-92-4P 1438903-93-5P
 1438903-94-6P 1438903-95-7P 1438903-96-8P 1438903-97-9P
 1438903-98-0P 1438903-99-1P 1438904-00-7P 1438904-01-8P
 1438904-02-9P 1438904-03-0P 1438904-04-1P 1438904-05-2P
 1438904-06-3P 1438904-07-4P 1438904-08-5P 1438904-09-6P
 1438904-10-9P 1438904-11-0P 1438904-12-1P 1438904-13-2P
 1438904-14-3P 1438904-15-4P 1438904-16-5P 1438904-17-6P
 1438904-18-7P 1438904-19-8P 1438904-20-1P 1438904-21-2P
 1438904-22-3P 1438904-23-4P 1438904-24-5P 1438904-25-6P
 1438904-26-7P 1438904-27-8P 1438904-28-9P 1438904-29-0P
 1438904-30-3P 1438904-31-4P 1438904-32-5P 1438904-33-6P
 1438904-34-7P 1438904-35-8P 1438904-36-9P 1438904-37-0P
 1438904-38-1P 1438904-39-2P 1438904-40-5P 1438904-41-6P
 1438904-42-7P 1438904-43-8P 1438904-45-0DP, PEGylated 1438904-46-1P
 1438904-47-2P 1438904-48-3P 1438904-49-4P 1438904-50-7P
 1438904-51-8DP, PEGylated 1438984-86-1P 1438985-17-1P 1438985-53-5P
 1438985-86-4P 1438986-45-8P 1438986-79-8DP, PEGylated 1438986-79-8P
 1438987-17-7DP, derivs. 1438987-17-7P 1438987-53-1DP, PEGylated
 1438987-53-1P 1438987-83-7P 1438988-15-8P 1438988-45-4P
 1438989-32-2P 1438991-37-7DP, PEGylated 1438991-40-2DP, PEGylated

1438993-18-0P 1438993-55-5P 1438993-90-8P 1438995-10-8DP, PEGylated
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP
 (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (amino acid sequence, fusion peptide comprising; prepn. and activity of
glucagon superfamily peptides exhibiting glucocorticoid
 receptor activity)

IT 1438995-10-8P 1438999-04-2P 1439000-19-7P 1439000-67-5P
 1439000-99-3P 1439010-23-7P 1439011-14-9P 1439082-72-0DP, PEGylated
 1439085-78-5DP, PEGylated 1439086-71-1DP, PEGylated 1439087-60-1DP,
 PEGylated 1439088-53-5DP, PEGylated 1439089-38-9DP, PEGylated
 1439090-10-4DP, PEGylated 1439090-81-9DP, PEGylated 1439091-72-1DP,
 PEGylated 1439092-53-1DP, PEGylated 1439094-34-4DP, PEGylated
 1439095-49-4DP, PEGylated 1439096-18-0DP, PEGylated 1439097-60-5DP,
 PEGylated 1439098-37-9P 1439099-27-0P 1439100-18-1DP, PEGylated
 1439101-60-6P 1439103-26-0P 1439104-18-3P 1439109-31-5P
 1439109-93-9P 1439110-78-7DP, PEGylated 1439316-20-7P 1439317-05-1P
 1439317-72-2P 1439318-37-2P 1439320-17-8P 1439321-13-7P
 1439321-94-4P 1439322-87-8P 1439323-50-8P 1439324-13-6P
 1439324-87-4P 1439325-76-4P 1439326-35-8P 1439326-52-9P
 1439330-82-1P 1439331-39-1DP, PEGylated 1439332-22-5P
 1439332-64-5DP, PEGylated 1439333-24-0P 1439334-02-7DP, PEGylated
 1439334-69-6DP, PEGylated 1439335-63-3P 1439336-21-6P
 1439337-05-9DP, PEGylated 1439337-77-5DP, PEGylated 1439338-34-7P
 1439338-94-9DP, PEGylated 1439339-73-7P 1439340-25-6P
 1439340-95-0DP, PEGylated 1439341-66-8P 1439342-95-6P 1439343-62-0P
 1439344-18-9P 1439345-14-8P 1439346-01-6P 1439346-62-9P
 1439347-17-7P 1439347-75-7P 1439348-49-8P 1439349-13-9P
 1439349-76-4P 1439350-38-5P 1439351-28-6P 1439351-88-8P
 1439352-45-0P 1439353-41-9P 1439354-07-0P 1439354-58-1P
 1439354-91-2P 1439356-29-2P 1439356-32-7P 1439356-39-4P
 1439356-43-0P 1439356-49-6DP, PEGylated 1439357-17-1DP, PEGylated
 1439357-18-2DP, PEGylated 1439357-19-3DP, PEGylated 1439357-21-7DP,
 PEGylated 1439357-22-8P 1439357-23-9P 1439357-24-0P 1439357-26-2P
 1439357-27-3P 1439357-29-5P 1439357-30-8P 1439357-31-9P
 1439357-33-1P 1439357-35-3P 1439357-36-4P 1439357-37-5P
 1439357-55-7P 1439357-61-5P 1439357-66-0P 1439357-68-2P
 1439357-69-3P 1439357-79-5P 1439357-80-8P 1439357-82-0P
 1439357-83-1P 1439357-84-2P 1439357-85-3P 1439357-95-5P
 1439358-27-6P 1439358-31-2P 1439358-33-4P 1439358-65-2P
 1439363-88-8P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP
 (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (amino acid sequence, fusion peptide comprising; prepn. and activity of
glucagon superfamily peptides exhibiting glucocorticoid
 receptor activity)

IT 50-99-7, D-Glucose, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (blood; prepn. and activity of **glucagon** superfamily peptides
 exhibiting glucocorticoid receptor activity)

IT 60-92-4, CAMP
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (induction; prepn. and activity of **glucagon** superfamily
 peptides exhibiting glucocorticoid receptor activity)

IT 50-02-2, Dexamethasone
 RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use);
 BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (peptide comprising; prepn. and activity of **glucagon**
 superfamily peptides exhibiting glucocorticoid receptor activity)

IT 50-04-4, Cortisone acetate 50-23-7, Cortisol 50-24-8, Prednisolone
 53-03-2, Prednisone 83-43-2, Methylprednisolone 124-94-7,
 Triamcinolone 378-44-9, Betamethasone 4419-39-0, Beclometasone
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (peptide comprising; prepn. and activity of **glucagon**
 superfamily peptides exhibiting glucocorticoid receptor activity)

IT 59392-49-3, Gastric inhibitory peptide
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (prepn. and activity of **glucagon** superfamily peptides
 exhibiting glucocorticoid receptor activity)

IT 9007-92-5D, **Glucagon**, analogs, biological studies

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT 89750-14-1, **Glucagon**-like peptide I
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT 7698-93-3P 58534-72-8P 197704-28-2P, Cholest-5-ene-3-carboxylic acid 1350306-69-2P 1350306-70-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT 41164-36-7DP, **conjugates** with **GLP-1** analogs 1438897-10-9DP, **conjugates** with **GLP-1** analogs 1438897-11-0DP, **conjugates** with **GLP-1** analogs 1438897-14-3DP, **conjugates** with **GLP-1** analogs
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT 50-28-2, 17 β -Estradiol, reactions 50-50-0, β -Estradiol 3-benzoate 53-16-7, Estrone, reactions 105-36-2, Ethyl 2-bromoacetate 108-30-5, Succinic anhydride, reactions 156-57-0, 2-Mercaptoethylamine hydrochloride 1743-60-8, Estradiol 17-acetate 2127-03-9, Aldrithiol-2 7693-46-1, 4-Nitrophenyl chloroformate 15231-41-1 29022-11-5 35661-39-3 35661-40-6 35661-60-0 57260-73-8 68858-20-8 71989-14-5 71989-23-6 71989-26-9 71989-31-6 71989-33-8 71989-38-3 73731-37-0 81186-33-6, ϵ -Maleimidocaproic acid hydrazide 94744-50-0 103213-32-7 109425-51-6 132327-80-1 143824-78-6 167015-23-8 167393-62-6 200616-39-3 201531-88-6 1350306-73-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT 41164-35-6P 79360-11-5P 106139-15-5P 259815-84-4P 1350306-67-0P 1350306-71-6P 1350306-72-7P 1350306-74-9P 1350306-75-0P 1426080-15-0P 1438897-12-1P 1438897-13-2DP, **conjugates** with **GLP-1** analogs 1438897-15-4P 1438897-16-5P 1438897-17-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT 79360-11-5DP, **conjugates** with **GLP-1** analogs 259815-84-4DP, **conjugates** with **GLP-1** analogs 1438897-16-5DP, **conjugates** with **GLP-1** analogs 1438897-17-6DP, **conjugates** with **GLP-1** analogs
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT 54249-88-6, Dipeptidyl peptidase IV
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(stability against; prepn. and activity of **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

IT 1233146-86-5 1312424-88-6 1350322-94-9 1350322-96-1 1350322-98-3 1350323-00-0 1350323-03-3 1350323-05-5 1350323-07-7 1350323-09-9 1350323-11-3 1350323-13-5 1352946-16-7 1438915-17-3 1438915-18-4 1438915-19-5 1438915-20-8 1438915-21-9 1438915-22-0 1438915-23-1 1438915-24-2 1438915-25-3 1438915-26-4 1438915-27-5 1438915-28-6 1438915-29-7 1438915-30-0 1438915-31-1 1438915-32-2 1438915-33-3 1438915-34-4 1438915-35-5 1438915-36-6 1438915-37-7
RL: PRP (Properties)
(unclaimed protein sequence; **glucagon** superfamily peptides)

IT exhibiting glucocorticoid receptor activity)
1438915-16-2
RL: PRP (Properties)
(unclaimed sequence; **glucagon** superfamily peptides exhibiting glucocorticoid receptor activity)

=> s CONJUGATES AND "Glucagon" AND "Glucagon-like peptide 1" AND FORMULA AND PD<20151231

L4 12 FILE CAPLUS
L5 0 FILE REGISTRY

TOTAL FOR ALL FILES

L6 12 CONJUGATES AND "GLUCAGON" AND "GLUCAGON-LIKE PEPTIDE 1" AND FORMULA AND PD<20151231

=> d l6 1-12 ABS BIB

L6 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2019 ACS on STN

AB The present invention features a compd. having the **formula** A-X-B, where A is peptide vector capable of enhancing transport of the compd. across the blood-brain barrier or into particular cell types, X is a linker, and B is a GLP-1 agonist (e.g., exendin-4 or an exendin-4 analog). The compds. of the invention can be used to treat any disease where increased GLP-1 activity is desired, for example, metabolic diseases, such as obesity and diabetes.

[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

AN 2016:2062166 CAPLUS [Full-text](#)

DN 167:375109

TI **Conjugates** of glp-1 agonists and uses thereof

IN Castaigne, Jean-Paul; Demeule, Michel; Gagnon, Catherine; Lawrence, Betty

PA Angiochem, Inc., Can.

SO U.S., No pp. given

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
US 8921314	B2	20141230	English	PDF PDF+ Interactive
US 20120015876	A1	20120119	English	PDF
WO 2010043047	A1	20100422	English	PDF PDF+ Interactive

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 8921314	B2	20141230	US 2011-13124013	20110922
US 20120015876	A1	20120119		

WO 2010043047	A1	20100422	WO 2009-CA1476	20091015
----------------------	-----------	-----------------	-----------------------	-----------------

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2008-61105618 P 20081015

WO 2009-CA1476 W 20091015

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L6 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2019 ACS on STN

AB The invention provides a conjugate comprising a biomol. selected from (1) human growth differentiation factor 15 (GDF15), homologs, variants, mutants, fragments and other modified forms thereof or a dimer thereof; (2) an apelin agonist peptide, (3) oxytocin receptor agonist peptide, (4) serelaxin, (5) Neuropeptide FF, (6) a prolactin-inducible peptide, (7) an fibroblast growth factor 23 peptide (8) Agouti-related protein and (9) a siRNA; or an amide, an ester or a pharmaceutically acceptable salt thereof. linked to a fatty acid via a linker wherein the fatty acid has the following **formulas**: $\text{HOOC}[(\text{CH}_2)_n\text{R}_2][(\text{CH}_2)_m\text{R}_3]\text{R}_1$, $\text{HOOCCH}[(\text{CH}_2)_p\text{R}_4]\text{COOH}$ or $\text{HOOC}(\text{CH}_2)_p\text{R}_4\text{COOH}$ [R1 = COOH, H; R2-4 = independently H, OH, COOH, CH:CH₂, C:CH; Ak = a branched C6-30 alkylene; n, m, p = independently of each other an integer between 6 and 30,] e.g., $\text{N}_3(\text{CH}_2\text{CH}_2\text{O})_{23}\text{CH}_2\text{CH}_2\text{NHCOC}[(\text{CH}_2)_{10}\text{COOH}]_2\text{COOH}$ (I), or an amide, ester or pharmaceutically acceptable salt thereof. The invention also relates to a method for manufg. the **conjugates** of the invention and to their therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alc. and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The invention further provides a combination of pharmacol. active agents and a pharmaceutical compn. Thus, esterification of 11-bromoundecanoic acid with benzyl alc., alkylation of dibenzyl malonate with benzyl 11-bromoundecanoate (II), alkylation of tribenzyl undecane-1,1,11-tricarboxylate with II, debenzylation of tetrabenzyl henicosane-1,11,11,21-tetracarboxylate, treatment of henicosane-1,11,11,21-tetracarboxylic acid with NHS and reaction of 11-[[2,5-Dioxopyrrolidin-1-yl]oxy]carbonyl]henicosane-1,11,21-tricarboxylic acid with $\text{N}_3(\text{CH}_2\text{CH}_2\text{O})_{23}\text{CH}_2\text{CH}_2\text{NH}_2$ gave I and $\text{N}_3(\text{CH}_2\text{CH}_2\text{O})_{23}\text{CH}_2\text{CH}_2\text{NHCOC}[(\text{CH}_2)_{10}\text{COOH}]\text{COOH}$. A bicyclononyl (BCN) His-labeled hGDF15 (prepn. given) was conjugated with I in the presence of NaOAc at pH = 4.5. The resulting conjugate possessed a significant longer duration of action as compared to non-conjugated hGDF15 and as compared to pegylated hGDF15.

[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

AN 2015:2096591 CAPLUS [Full-text](#)

DN 164:162861

TI Preparation of novel fatty acids and their use in conjugation to biomolecules

IN Barnes, David Weninger; Yamada, Ken; Ibebunjo, Chikwendu; Duttaroy, Alokesh; Kirman, Louise Clare; Bruce, Alexandra Marshall; Usera, Aimee Richardson; Zecri, Frederic; Yuan, Jun; Lou, Changgang; Kanter, Aaron; Bose, Avirup

PA Novartis AG, Switz.

SO PCT Int. Appl., 293pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2015200078	A1	20151230	English	PDF PDF+ Interactive
US 20160030585	A1	20160204	English	PDF
CA 2953480	A1	20151230	English	PDF
AU 2015280351	A1	20161208	English	PDF
AU 2015280351	B2	20180705	English	PDF
KR 2017020878	A	20170224	Korean	PDF
JP 2017519024	T	20170713	Japanese	PDF
CN 107073130	A	20170818	Chinese	PDF
US 20180326079	A1	20181115	English	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2015200078	A1	20151230	WO 2015-US36328	20150618
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM				
US 20160030585	A1	20160204	US 2015-14738272	20150612

CA 2953480	A1	20151230	CA 2015-2953480	20150618
AU 2015280351	A1	20161208	AU 2015-280351	20150618
AU 2015280351	B2	20180705		
IL 248990	A	20170131	IL 2015-248990	20150618
KR 2017020878	A	20170224	KR 2017-7001520	20150618
EP 3157571	A1	20170426	EP 2015-732508	20150618
R: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BA, ME				
CR 20160596	A	20170508	CR 2016-596	20150618
JP 2017519024	T	20170713	JP 2016-574916	20150618
CN 107073130	A	20170818	CN 2015-80033910	20150618
BR 112016028884	A2	20171031	BR 2016-112016028884	20150618
AR 100939	A1	20161109	AR 2015-101998	20150623
IN 201617040617	A	20170331	IN 2016-17040617	20161128
MX 2016017395	A	20170501	MX 2016-17395	20161220
US 20180326079	A1	20181115	US 2018-15985060	20180521
PRAI US 2014-62015862	P	20140623		
US 2014-62082327	P	20141120		
US 2015-62107016	P	20150123		
US 2015-14738272	A3	20150612		
WO 2015-US36328	W	20150618		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 164:162861; MARPAT 164:162861

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2019 ACS on STN

AB Disclosed herein are insulin agonist peptides conjugated to incretins wherein the insulin/incretin conjugate has agonist activity at both the insulin receptor and the corresponding incretin receptor. The **formula** of the conjugate is CH(NH₂)(COOH)-(CH₂)_n-NR₁R₂ (R₁, R₂ = H, C₁-C₁₈ alkyl, (C₁-C₁₈ alkyl)OH et al). Insulin is a proven therapy for the treatment of juvenile-onset diabetes and later-stage adult-onset diabetes. The peptide is biosynthesized as a larger linear precursor of low potency (approx. 2% to 9% of native insulin), named proinsulin. Proinsulin is proteolytically converted to insulin by the selective removal of a 35-residue connecting peptide (C peptide).

PatentPak PDF

AN 2014:1653449 CAPLUS [Full-text](#)

DN 161:572939

TI Insulin agonist peptide-incretin **conjugates** for treatment of juvenile and adult-onset diabetes

IN Dimarchi, Richard D.; Parody, Todd; Han, Jie; Li, Pengyun

PA Indiana University Research and Technology Corporation, USA

SO PCT Int. Appl., 197pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2014158900	A1	20141002	English	PDF
AU 2014241743	A1	20150917	English	PDF
AU 2014241743	B2	20180705	English	PDF
KR 2015131213	A	20151124	Korean	PDF
CN 105324397	A	20160210	Chinese	PDF
JP 2016512255	T	20160425	Japanese	PDF
JP 6538645	B2	20190703	Japanese	PDF
RU 2678134	C2	20190123	Russian	PDF
US 20160024169	A1	20160128	English	PDF
US 20180194827	A1	20180712	English	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2014158900	A1	20141002	WO 2014-US20801	20140305
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM				

CA 2904332	A1	20141002	CA 2014-2904332	20140305
-------------------	-----------	-----------------	------------------------	-----------------

AU 2014241743	A1	20150917	AU 2014-241743	20140305
AU 2014241743	B2	20180705		

KR 2015131213	A	20151124	KR 2015-7028780	20140305
EP 2970511	A1	20160120	EP 2014-773636	20140305
R: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BA, ME				
CN 105324397	A	20160210	CN 2014-80027381	20140305
JP 2016512255	T	20160425	JP 2016-500671	20140305
JP 6538645	B2	20190703		
BR 112015023071	A2	20170718	BR 2015-112015023071	20140305
RU 2678134	C2	20190123	RU 2015-143472	20140305
US 20160024169	A1	20160128	US 2015-14774357	20150910
IN 2015DN08712	A	20160715	IN 2015-DN8712	20150923
US 20180194827	A1	20180712	US 2017-15846485	20171219

PRAI

US 2013-61783491	P	20130314
WO 2014-US20801	W	20140305
US 2015-14774357	B1	20150910

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 161:572939

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2019 ACS on STN

AB The present invention provides a compn. of the **formula**: [FGF21 -1st Linker]-[Ab]- [2nd-Linker-Ex4]; wherein FGF21 is an FGF21 homolog; and Ex4 is an Exendin 4 homolog; and Ab is an aldolase catalytic antibody or antigen binding portion thereof. The 1st linker is covalently attached to the side chain of a protein-linking residue in FGF21 and to a combining site of the antibody, and the 2nd linker is covalently attached to the side chain of a peptide-linking residue in Ex4 and to a combining site of the antibody, and wherein the first and second linker are the same or different. Various uses of the compds. are provided, including methods to prevent or treat diabetes or diabetes-related conditions.

[PatentPak PDF](#)

AN 2013:1009392 CAPLUS [Full-text](#)

DN 159:159296
 TI Anti-diabetic compounds comprising fibroblast growth factor FGF21
 covalently attached to combining site of antibody and Exendin 4 with
 prepared linkers
 IN Annathur, Gopinath Vedachalam; Balu, Palani; Finn, Rory Francis; Huang,
 Jie; Laurent, Olivier Alexandre; Levin, Nancy Jane; Luksha, Nicholas Gary;
 Martin, Joseph Patrick, Jr.; Moskowitz, Haim; Palanki, Moorthy
 Sitharamaiah Suriyanarayana; Pozzo, Mark John; Waszak, Gregory Allan; Xie,
 Jin
 PA Pfizer Inc., USA; CovX Technologies Ireland Limited
 SO PCT Int. Appl., 179pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1
 PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2013093720	A2	20130627	English	PDF
WO 2013093720	A3	20131024	English	PDF
US 20130164310	A1	20130627	English	PDF
US 9163227	B2	20151020	English	PDF
AU 2012356219	A1	20140619	English	PDF
AU 2012356219	B2	20160331	English	PDF
KR 2014105594	A	20140901	Korean	PDF
KR 1640697	B1	20160718	Korean	PDF
CN 104066438	A	20140924	Chinese	PDF
CN 104066438	B	20150923	Chinese	PDF
EP 2793928	B1	20170315	English	PDF
JP 2015506926	T	20150305	Japanese	PDF
JP 6165168	B2	20170719	Japanese	PDF
ES 2623786	T3	20170712	Spanish	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2013093720	A2	20130627	WO 2012-IB57227	20121212
WO 2013093720	A3	20131024		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM			
CA 2859969	A1	20130627	CA 2012-2859969	20121212
US 20130164310	A1	20130627	US 2012-13712873	20121212
US 9163227	B2	20151020		
AU 2012356219	A1	20140619	AU 2012-356219	20121212
AU 2012356219	B2	20160331		
IL 233206	A	20140731	IL 2012-233206	20121212
KR 2014105594	A	20140901	KR 2014-7020397	20121212
KR 1640697	B1	20160718		
CN 104066438	A	20140924	CN 2012-80063933	20121212
CN 104066438	B	20150923		
EP 2793928	A2	20141029	EP 2012-816137	20121212
EP 2793928	B1	20170315		
R:	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO,			

RS, SE, SI, SK, SM, TR

JP 2015506926	T	20150305	JP 2014-548277	20121212
JP 6165168	B2	20170719		
TW I560202	B	20161201	TW 2012-147080	20121212
BR 112014014898	A2	20170613	BR 2014-112014014898	20121212
ES 2623786	T3	20170712	ES 2012-816137	20121212

ZA 2014003755	A	20151125	ZA 2014-3755	20140522
IN 2014DN04302	A	20160831	IN 2014-DN4302	20140527

MX 2014007626	A	20140916	MX 2014-7626	20140620
HK 1200726	A1	20160826	HK 2015-101306	20150205
PRAI US 2011-61579609	P	20111222		
US 2012-61644831	P	20120509		
WO 2012-IB57227	W	20121212		


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 159:159296

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L6 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2019 ACS on STN

GI



AB Provided herein are **glucagon** superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compns. and kits of the **conjugates** of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the **conjugates** of the invention. The **glucagon** superfamily peptide **conjugates** of the invention can be represented by the following **formula**: Q-L-Y wherein Q is a **glucagon** superfamily peptide, Y is a GR ligand, and L is a linking group or a bond. The

glucagon superfamily peptide (Q) in some embodiments can be a **glucagon** related peptide that exhibits agonist activity at the **glucagon** receptor, agonist activity at the GLP-1 receptor, agonist activity at the GIP receptor, co-agonist activity at the **glucagon** and GLP-1 receptors, co-agonist activity at the **glucagon** and GIP receptors, co-agonist activity at the GLP-1 and GIP receptors, or triagonist activity at the **glucagon**, GIP, and GLP-1 receptors. In some embodiments, the **glucagon** related peptide exhibits antagonist activity at the **glucagon**, GLP-1 or GIP receptor.

PatentPak PDF

AN 2013:796014 CAPLUS [Full-text](#)

DN 159:36059

TI **Glucagon** superfamily peptides exhibiting glucocorticoid receptor activity

IN Dimarchi, Richard D.; Yang, Bin

PA Indiana University Research and Technology Corporation, USA

SO PCT Int. Appl., 420pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2013074910	A1	20130523	English	PDF
US 20130157934	A1	20130620	English	PDF
US 8859491	B2	20141014	English	PDF
CN 103957927	A	20140730	Chinese	PDF
CN 103957927	B	20161109	Chinese	PDF
KR 2014097151	A	20140806	Korean	PDF
EP 2780031	B1	20180307	English	PDF
JP 2015504431	T	20150212	Japanese	PDF
JP 6324315	B2	20180516	Japanese	PDF
ES 2672880	T3	20180618	Spanish	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2013074910	A1	20130523	WO 2012-US65492	20121116
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM				
CA 2847246	A1	20130523	CA 2012-2847246	20121116
US 20130157934	A1	20130620	US 2012-13679121	20121116
US 8859491	B2	20141014		
CN 103957927	A	20140730	CN 2012-80049164	20121116
CN 103957927	B	20161109		
KR 2014097151	A	20140806	KR 2014-7012192	20121116
EP 2780031	A1	20140924	EP 2012-849285	20121116
EP 2780031	B1	20180307		
R: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR				
JP 2015504431	T	20150212	JP 2014-542489	20121116
JP 6324315	B2	20180516		
BR 112014007124	A2	20170613	BR 2014-112014007124	20121116

ES 2672880 T3 20180618 ES 2012-849285 20121116
MX 2014003579 A 20150410 MX 2014-3579 20140325
IN 2014DN03510 A 20160520 IN 2014-DN3510 20140501
PRAI US 2011-61561094 P 20111117
WO 2012-US65492 W 20121116
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 159:36059; MARPAT 159:36059
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2019 ACS on STN
AB Disclosed is a mol. probe for imaging the pancreatic islet by targeting
GLP-1R ([glucagon-like peptide 1](#) receptor). Specifically disclosed
is a mol. probe which comprises a polypeptide represented by [formula](#)
(1), (2) or (3) or a polypeptide having homol. with the polypeptide:
Z-HGEGTFTSDLSXQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 (1) (SEQ ID NO:1);
Z-HGEGTFTSDLSKQMEEEAVRLFIEWLXNGGPSSGAPPPS-NH2 (2) (SEQ ID NO:2); and
B-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 (3) (SEQ ID NO:3). In
[formulas](#) (1) and (2), "X" represents a lysine residue in which an amino
group in the side chain is labeled with a radioactive nuclide; and "Z-"
means that an α -amino group located at the N-terminal is unmodified
or modified with a modification group having no charge. In [formula](#) (3),
"B-" means that an α -amino group located at the N-terminal is
labeled with a radioactive nuclide. In [formulas](#) (1), (2) and (3),
"-NH2" means that a carboxyl group located at the C-terminal is amidated.

AN 2011:753061 CAPLUS [Full-text](#)
DN 155:87080
TI Molecular probes for specific imaging of pancreatic islet
IN Saji, Hideo; Inagaki, Nobuya; Toyoda, Kentaro; Kimura, Hiroyuki; Hirao,
Konomu; Nagakawa, Kenji; Matsuda, Hirokazu
PA Kyoto University, Japan; Arkray, Inc.
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1
PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
KR 2012080653	A	20120717	Korean	PDF
KR 1550006	B1	20150903	Korean	PDF
CN 102695527	A	20120926	Chinese	PDF
CN 102695527	B	20150311	Chinese	PDF
EP 2510951	A1	20121017	English	PDF
EP 2510951	A9	20140108	English	PDF
EP 2510951	B1	20160713	English	PDF
JP 5700835	B2	20150415	Japanese	PDF
US 20110206605	A1	20110825	English	PDF
US 8980220	B2	20150317	English	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2011071083	A1	20110616	WO 2010-JP72041	20101208
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

KR 2012080653 A 20120717 KR 2012-7014631 20101208
KR 1550006 B1 20150903

CN 102695527 A 20120926 CN 2010-80056397 20101208
CN 102695527 B 20150311

EP 2510951 A1 20121017 EP 2010-836003 20101208
EP 2510951 A9 20140108
EP 2510951 B1 20160713
R: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,
HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO,
RS, SE, SI, SK, SM, TR

JP 5700835 B2 20150415 JP 2011-507740 20101208

US 20110206605 A1 20110825 US 2010-964486 20101209
US 8980220 B2 20150317

IN 2012CN05424 A 20140214 IN 2012-CN5424 20120621
IN 309615 A1 20190329
PRAI JP 2009-280396 A 20091210
US 2009-61285293 P 20091210
JP 2010-125983 A 20100601
US 2010-61350732 P 20100602
US 2010-61388948 P 20101001
WO 2010-JP72041 W 20101208

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 155:87080

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2019 ACS on STN

AB The present invention features a compd. having the **formula** A-X-B, where
A is peptide vector capable of enhancing transport of the compd. across
the blood-brain barrier or into particular cell types, X is a linker, and
B is a GLP-1 agonist (e.g., exendin-4 or an exendin-4 analog). The
comps. of the invention can be used to treat any disease where increased
GLP-1 activity is desired, for example, metabolic diseases, such as
obesity and diabetes.

[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

AN 2010:503911 CAPLUS [Full-text](#)

DN 152:493497

TI **Conjugates** of glp-1 agonists and uses thereof

IN Castaigne, Jean-Paul; Demeule, Michel; Gagnon, Catherine; Lawrence, Betty

PA Angiochem Inc., Can.

SO PCT Int. Appl., 90pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2010043047	A1	20100422	English	PDF PDF+ Interactive
AU 2009304560	A1	20100422	English	PDF
CN 102245642	A	20111116	Chinese	PDF
JP 2012505637	T	20120308	Japanese	PDF
US 8921314	B2	20141230	English	PDF PDF+ Interactive
US 20120015876	A1	20120119	English	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2010043047 A1 20100422 WO 2009-CA1476 20091015
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,
ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE,
PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2009304560 A1 20100422 AU 2009-304560 20091015

CA 2740316 A1 20100422 CA 2009-2740316 20091015

EP 2346906 A1 20110727 EP 2009-820161 20091015

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, AL, BA, RS

CN 102245642 A 20111116 CN 2009-80150216 20091015

JP 2012505637 T 20120308 JP 2011-531313 20091015

ZA 2011003044 A 20120725 ZA 2011-3044 20091015

BR 2009020209 A2 20151222 BR 2009-20209 20091015

MX 2011004017 A 20110624 MX 2011-4017 20110414

IN 2011CN03183 A 20120316 IN 2011-CN3183 20110509

US 8921314 B2 20141230 US 2011-13124013 20110922

US 20120015876 A1 20120119

PRAI US 2008-61105618 P 20081015

WO 2009-CA1476 W 20091015

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 152:493497

OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2019 ACS on STN

AB The invention relates to a prodrug or a pharmaceutically acceptable salt [D = N-contg. biol. active moiety; L = non-biol. active linker L1: R3R3aNCR2R2aX2NH*X1(:X2)XCR1R1aCO- (I) wherein the CO group is attached to the N of D by forming an amide bond; X = CR4R4a, NR4, CR4R4aCR5R5a, CR5R5aCR4R4a, CR4R4aNR6, NR6CR4R4a, CR4R4aO, OCR4R4a; X1 = C, NCN; X2 = CR7R7a, CR7R7aCR8R8a; X3 = O, S, NCN; R1, R1a, R2, R2a, R3, R3a, R4, R4a, R5, R5a, R6, R7, R7a, R8, R8a = independently H, alkyl; optionally, one or more of the pairs R1a/R4a, R1a/R5a, R4a/R5a, R7a/R8a form a chem. bond; optionally, one or more of the pairs R1/R1a, R2/R2a, R5/R5a, R7/R7a, R8/R8a are joined together with the atom to which they are attached to form a C3-7 cycloalkyl or 4-7 membered heterocyclyl; optionally, one or more of the pairs R1/R4, R1/R5, R1/R6, R4/R5, R4/R6, R7/R8, R2/R3 are joined together with the atoms to which they are attached to form a ring A; optionally, R3/R3a are joined together with the nitrogen atom to which they are attached to form a 4-7 membered heterocycle; A = Ph, naphthyl, indenyl, indanyl, tetralinyl; L1 is substituted with 1-4 groups L2-Z and optionally further substituted, provided that the H marked with asterisk in **formula** I is not replaced by a substituent; L2 = a single bond or a spacer; Z = a carrier group]. The invention also related to A-L [A = a leaving group], pharmaceutical compn. comprising said prodrugs and their use as medicaments. Thus, a reversible PEG-linker-fluorescein labeled exendin conjugate PEG-SCH2CH2CONHCH(CH2CONHR)CONHCH2CH2NMe2 (II) [R = exendin(εK27-fluorescein)] was prepd. The half-life of in vivo linker hydrolysis was detd. to be 115 h for II which is in excellent correlation to the half-life of in vitro linker hydrolysis of 120 h.

[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

AN 2009:948762 CAPLUS [Full-text](#)

DN 151:245999

TI Prodrugs containing a drug linker conjugate, especially (pegylated) linker-exendin-4, and fatty acid-exendin **conjugates**

IN Cleemann, Felix; Hersel, Ulrich; Kaden, Silvia; Rau, Harald; Wegge, Thomas

PA Ascendis Pharma AS, Den.

SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2009095479	A2	20090806	English	PDF PDF+ Interactive
AU 2009209565	A1	20090806	English	PDF
AU 2009209565	B2	20130919	English	PDF
CA 2712224	C	20160308	English	PDF
EP 2237799	B1	20190410	English	PDF
CN 101980725	A	20110223	Chinese	PDF
CN 101980725	B	20130612	Chinese	PDF
JP 2011510954	T	20110407	Japanese	PDF
JP 5588354	B2	20140910	Japanese	PDF
EP 2596805	A1	20130529	English	PDF
US 8906847	B2	20141209	English	PDF
RU 2676324	C2	20181228	Russian	PDF
JP 2014193908	A	20141009	Japanese	PDF
US 20150057221	A1	20150226	English	PDF
US 20170100490	A1	20170413	English	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009095479	A2	20090806	WO 2009-EP51079	20090130
WO 2009095479	A3	20091001		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2009209565	A1	20090806	AU 2009-209565	20090130
AU 2009209565	B2	20130919		
CA 2712224	A1	20090806	CA 2009-2712224	20090130
CA 2712224	C	20160308		
EP 2237799	A2	20101013	EP 2009-706788	20090130
EP 2237799	B1	20190410		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, RS			
CN 101980725	A	20110223	CN 2009-80111088	20090130
CN 101980725	B	20130612		
JP 2011510954	T	20110407	JP 2010-544717	20090130
JP 5588354	B2	20140910		
IL 207150	A	20121231	IL 2009-207150	20090130
EP 2596805	A1	20130529	EP 2013-156350	20090130
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, RS			
MX 2010008024	A	20101221	MX 2010-8024	20100722
IN 2010CN04702	A	20110211	IN 2010-CN4702	20100727
ZA 2010005413	A	20120425	ZA 2010-5413	20100729

	US 20110053848	A1	20110303	US 2010-865693	20101008
	US 8906847	B2	20141209		
	HK 1152240	A1	20140314	HK 2011-106352	20110621
	RU 2676324	C2	20181228	RU 2014-122036	20140530
	JP 2014193908	A	20141009	JP 2014-115482	20140604
	US 20150057221	A1	20150226	US 2014-14528362	20141030
	US 20170100490	A1	20170413	US 2016-15385179	20161220
PRAI	EP 2008-150973	A	20080201		
	EP 2008-170872	A	20081205		
	EP 2009-706788	A3	20090130		
	JP 2010-544717	A3	20090130		
	RU 2010-136023	A3	20090130		
	WO 2009-EP51079	W	20090130		
	US 2010-865693	A1	20101008		
	US 2014-14528362	A1	20141030		



ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS CASREACT 151:245999; MARPAT 151:245999
 OSC.G 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)

L6 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2019 ACS on STN
 AB The title fusion protein mainly comprises polypeptide 1 (composed of 30-40 amino acids) with hypoglycemic function, and polypeptide 2 (TrxA, GST, or His-Tag). The fusion protein can contain polymer for increasing the stability and hydrophobicity of the fusion protein and small-mol. compd. for promoting the transmembrane transfer of the fusion protein. The structural **formula** of the fusion protein is shown in the invention. The fusion protein has good hypoglycemic performance, high stability, and high activity, and can be taken by oral administration or injection.

AN 2008:1534262 CAPLUS [Full-text](#)
 DN 150:137046
 TI Hypoglycemic fusion peptides and **conjugates** for treating diabetes, obesity, senile dementia or myocardial infarction
 IN Yao, Wenbing; Gao, Mingming; Tian, Hong; Gao, Xiangdong
 PA China Pharmaceutical University, Peop. Rep. China
 SO Faming Zhuanli Shenqing, 17pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1
 PPPI

	PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
	-----	----	-----	-----	-----
	CN 101328221	B	20110323	Chinese	PDF
PI					
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	CN 101328221	A	20081224	CN 2008-10023447	20080414
	CN 101328221	B	20110323		
PRAI	CN 2008-10023447		20080414		
OS	MARPAT 150:137046				

L6 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2019 ACS on STN
 GI



AB The invention is related to the prepn. of novel peptides AX_n [A = peptide-derived radical, produced by n-fold removal of 1 H from the N-terminal amino group and/or from the amino group of one or more lysine residues of the peptide; n = 1-20; R₁₋₄ = hydrogen, hydroxy, C₁₋₆-alkyl, C₂₋₆ alkenyl, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkoxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₃₋₈ cycloalkylthio, C₁₋₆ alkylamino, aryl, or arylthio, etc.; any two of R₁₋₄ taken together form a 5-7 membered ring; or any one of R₁₋₄ is covalently bound to Z, forming a 5-7 membered ring; Z = a valence-bond or a diradical with a mol. wt. ≤ 750 Da and chosen in a way, that a compd. of the **formula I** has a soly. in water of at least 0.10 mg/mL at room temp. and a pH in the range of 3.0 to 11.0.] with biodegradable and transient pegylation, such as GLP-1, exendin, growth hormone, and blood coagulation factor VIII, and to their pharmaceutical compns. useful as medicaments. The novel compds. provided drugs with a protracted profile of action. Thus, reacting Boc-Gly-Pro-OH with Nε26[γ-(hexadecanoyl)glutamyl](Arg34)GLP-1 (7-37), cleavage of the tert-butoxycarbonyl group, and treatment of the peptide intermediate with N-[mPEG(30k)yl]-4-[O-(N-hydroxysuccinimidyl)carbonyloxy]-3-methoxyphenylacetamide [mPEG(30k) = poly(ethylene glycol) monomethyl ether with a mol. wt. of approx. 30 kDa] gave mPeg(30k)-NH-CO-CH₂-C₆H₃(OMe)O-CO-Gly-Pro-[Nε26[γ-(hexadecanoyl)glutamyl](Arg34)G LP-1 (7-37)] which effectively lowered the blood glucose levels in db/db mice for a period of more than 3 days, as compared to the control.

[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

AN 2008:1185651 CAPLUS [Full-text](#)

DN 149:426266

TI Preparation of therapeutic peptide compounds with transient biodegradable pegylation

IN Zaragoza, Florencio Doerwald; Pesckhe, Bernd; Zundel, Magali

PA Novo Nordisk A/S, Den.

SO PCT Int. Appl., 63pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2008116913	A2	20081002	English	PDF PDF+ Interactive
US 20130109704	A1	20130502	English	PDF
US 9340544	B2	20160517	English	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008116913	A2	20081002	WO 2008-EP53658	20080327
WO 2008116913	A3	20090115		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

US 20130109704	A1	20130502	US 2012-13720956	20121219
US 9340544	B2	20160517		
PRAI EP 2007-105091	A	20070328		
DK 2007-482	A	20070328		
US 2007-60908503	P	20070328		
WO 2008-EP53648	A	20080327		
WO 2008-EP53658	A	20080327		

US 2010-593194 A3 20100129
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 149:426266; MARPAT 149:426266
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L6 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2019 ACS on STN
AB The present invention concerns new pharmaceutical formulations based on aq. colloidal suspensions for sustained release of active ingredient(s) (AI) in particular, protein(s) and peptide(s), as well as the applications, esp. therapeutic, of these formulations. This formulation comprises an aq. colloidal suspension with low viscosity based on micrometric particles of amphiphilic polymer PO that is biodegradable, hydrosol. and carrying hydrophobic groups (HG) -alpha-tocopherol- and ionizable hydrophilic groups (IG) -Glu-, ionized at least in part, said particles being suitable for spontaneously combining non-covalently with an AI at pH = 7.0 under isotonic conditions; and with a size between 0.5 and 100 µm. This suspension contains multivalent ions (Mg++) with a polarity opposite that of IG groups of the PO, the ratio r fulfilling the **formula** (A) where - n is the valence of said multivalent ions (MI) is the molar of multivalent ions, (IG) is the molar concn. of ionizable groups IG, is between 0.3 and 10. A suspension of polyglutamic acid grafted with hGH was prepd. and was acidified with HCl and pptd. with a soln. of 1M magnesium chloride and centrifuged to obtain microparticles having 122.88 mg/g polymer and 4.9 mg/g hGH. Pharmacokinetic of hGH was studied in dogs.

PatentPak PDF

AN 2007:1419960 CAPLUS Full-text
DN 148:39719
TI Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
IN Bonnet Gonnet, Cecile; Chognot, David; Soula, Olivier; Constancis, Alain
PA Flamel Technologies, Fr.
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1
PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2007141344	A2	20071213	French	PDF
AU 2007255367	A1	20071213	English	PDF
AU 2007255367	B2	20120802	English	PDF
EP 2043600	B1	20170726	French	PDF
KR 1463952	B1	20141126	Korean	PDF
CN 101466353	B	20140903	Chinese	PDF
JP 5351015	B2	20131127	Japanese	PDF
KR 2014109512	A	20140915	Korean	PDF
ES 2642095	T3	20171115	Spanish	PDF


PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007141344	A2	20071213	WO 2007-EP55720	20070611
WO 2007141344	A3	20080410		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
FR 2902007	A1	20071214	FR 2006-5152	20060609
FR 2902007	B1	20120113		

AU 2007255367 AU 2007255367	A1 B2	20071213 20120802	AU 2007-255367	20070611
CA 2653537 CA 2653537	A1 C	20071213 20140729	CA 2007-2653537	20070611
EP 2043600 EP 2043600 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS	A2 B1	20090408 20170726	EP 2007-730058	20070611
KR 2009040289 KR 1463952	A B1	20090423 20141126	KR 2009-7000533	20070611
CN 101466353 CN 101466353	A B	20090624 20140903	CN 2007-80021416	20070611
JP 2009539810 JP 5351015	T B2	20091119 20131127	JP 2009-513711	20070611
ZA 2008009864	A	20100331	ZA 2008-9864	20070611
BR 2007012142	A2	20120110	BR 2007-12142	20070611
IL 195269	A	20120924	IL 2007-195269	20070611
KR 2014109512 ES 2642095	A T3	20140915 20171115	KR 2014-7023768 ES 2007-730058	20070611 20070611
IN 2008CN06561 IN 284492	A A1	20090327 20170630	IN 2008-CN6561	20081201
MX 2008015665 PRAI FR 2006-5152 KR 2009-7000533 WO 2007-EP55720	A A A3 W	20090109 20060609 20070611 20070611	MX 2008-15665	20081208

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L6 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2019 ACS on STN
GI



● Li

AB The invention relates to novel N-terminal and C-terminal modifications of peptides that provide suitable derivatization sites to improve their pharmacokinetic properties. Modified peptides of **formula** Z1-A1-A2-A3-Gly-A5-Phe-Thr-A8-Asp-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-Phe-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-Z2 [A1, A2, to A40 = a bond, amino acid residues (defined), pegylated Cys, or Lys modified at Nε with a fatty acid; Z1 = H, acyl groups, e.g., aminobenzoyl, mercaptobenzoyl, CH3(CH2)nCO-; 5-mercaptopnicotinoyl, 2-[(2-mercaptoethyl)amino]nicotinoyl, 2-(2-mercapto-1H-benzimidazol-1-yl)acetyl, pegylated thiols contg. acyl

groups, etc.; n = 0-22; Z2 = OH, amino groups, e.g., NH(CH2)5CO2H, aminobenzoic acid, 2-carboxypiperidino, etc.] function as agonists of the GLP-1 receptor in vivo. Synthetic examples describe N-terminal modifying compds., which include (2-mercapto-1H-benzimidazol-1-yl)acetic acid, [(1-hexadecyl-1H-benzimidazol-2-yl)sulfanyl]acetic acid and lithium 2-[[1-[2-(tritylthio)ethyl]-1H-imidazol-2-yl]thio]acetate, for attachment to the peptide via solid phase synthesis. The peptides disclosed bind to the GLP-1 receptor present in the plasma membranes isolated from RINm5F cells with IC50 values in the range of 1.4-248 nM. Modified peptides of the invention provide a new therapy for patients with metabolic disorders such as those resulting from decreased endogenous insulin secretion, in particular diabetes or impaired glucose tolerance.

[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

AN 2006:1205743 CAPLUS [Full-text](#)

DN 146:8253

TI Preparation of N- and C-terminal modified peptides as **glucagon-like peptide 1** (GLP-1) receptor agonists and their use for treating diabetes and other metabolic disorders

IN Whelan, James; Lumb, Kevin; Clairmont, Kevin

PA Bayer Pharmaceuticals Corporation, USA

SO PCT Int. Appl., 104pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2006121860	A2	20061116	English	PDF PDF+ Interactive

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2006121860	A2	20061116	WO 2006-US17411	20060505
----------------------	-----------	-----------------	------------------------	-----------------

WO 2006121860	A3	20070412		
---------------	----	----------	--	--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

CA 2607566	A1	20061116	CA 2006-2607566	20060505
-------------------	-----------	-----------------	------------------------	-----------------

EP 1883419	A2	20080206	EP 2006-759154	20060505
-------------------	-----------	-----------------	-----------------------	-----------------

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

JP 2008539735	T	20081120	JP 2008-510259	20060505
----------------------	----------	-----------------	-----------------------	-----------------

PRAI US 2005-60678723 P 20050506

WO 2006-US17411 W 20060505

OS CASREACT 146:8253; MARPAT 146:8253

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

=>

PatBase - Search results 24 April 2020
Search query (4): 3 and Fc
Results: 11

Search history

Search 1: PN=(WO2017116205) (Results 1)

Search 2: TAC=(glucagon and agonist and linker and PEG) (Results 40)

Search 3: 2 and pd<20151231 (Results 31)

Search 4: 3 and Fc (Results 11)

1) Family number: 59069029 (US2015238631A)

© PatBase

Title: CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF

Abstract:


Disclosed herein are switches for regulating the activity of a chimeric antigen receptor effector cells (CAR-ECs). The switches generally comprise a chimeric antigen receptor-interacting domain (CAR-ID) and a target interacting domain (TID). The switch may further comprise a linker. Further disclosed herein are methods of using the switches for the treatment of one or more conditions or diseases in a subject in need thereof.

Classifications:

International (IPC 8-9): A61K A61K31/352 A61K31/4188 A61K38/00 A61K38/16 A61K38/17 A61K38/22 A61K38/26 A61K38/28 A61K39/00 A61K39/385 A61K39/395 A61K47/22 A61K47/48 A61K47/50 A61K47/54 A61K47/68 A61K49/00 A61P1/00 A61P1/04 A61P1/16 A61P13/12 A61P15/00 A61P17/02 A61P25/00 A61P25/04 A61P27/02 A61P29/00 A61P3/04 A61P3/06 A61P3/10 A61P35/00 A61P35/02 A61P37/00 A61P37/02 A61P37/04 A61P37/06 A61P43/00 A61P9/00 A61P9/04 A61P9/06 A61P9/10 A61P9/12 C07K C07K14/00 C07K14/395 C07K14/47 C07K14/505 C07K14/575 C07K14/605 C07K14/705 C07K14/715 C07K16/00 C07K16/10 C07K16/18 C07K16/28 C07K16/32 C07K16/40 C07K16/44 C07K16/46 C07K19/00 C12N C12N1/15 C12N1/19 C12N1/21 C12N15/00 C12N15/09 C12N15/63 C12N5/07 C12N5/0783 C12N5/10 C12P21/02 C12P21/08 G01N33/573 G01N33/574 G01N33/68 (Advanced/Invention); A61K38/00 A61K39/00 (Advanced/Non-invention)

CPC: A61K39/395 C07K14/4702 C07K14/70546 C07K2319/33 G01N33/57492 A61K47/48438 G01N33/573 G01N33/6863 C07K16/2809 C07K14/47 C07K14/7158 C07K2317/31 C07K2317/52 C07K2317/524 C07K2317/526 C07K2317/53 C07K2319/73 C07K2319/74 C07K2317/55 A61K47/6811 A61K47/6851 C07K14/395 C07K2319/01 C12N5/0636 A61K39/0002 A61K2039/515 A61K2039/572 A61K2039/70 A61K39/00 A61K2039/505 C07K16/18 C07K16/2869 C07K2319/30 C07K16/28 C07K19/00 A61K31/352 A61K31/4188 A61K49/0041 A61K49/0058 A61K47/6835 C07K16/2803 C07K16/2863 C07K16/2878 C07K16/2887 C07K16/44 C07K2317/522 C07K2317/567 C07K2317/622 A61K39/385 A61K39/3955 A61K47/6849 C07K16/2896 C07K16/40 A61P1/00 A61P1/04 A61P1/16 A61P13/12 A61P15/00 A61P17/02 A61P25/00 C07K14/575 C07K14/605 C07K16/1027 C07K2317/24 C07K2317/92 C07K2319/00 C07K2319/55 C12P21/02 A61K47/6817 C07K2317/14 A61K38/00 C07K16/32 A61P3/04 A61P25/04 A61P27/02 A61P29/00 A61P35/00 A61P35/02 A61P37/04 A61P43/00 A61P3/06 A61P3/10 A61P9/00 A61P9/04 A61P9/06 A61P9/10 A61P9/12 A61P37/00

PatBase - US2015238631 AA

FIG. 1

A61P37/02 A61P37/06 C07K14/505 C07K14/705 C07K16/46

US: 1/1 424/134.1 435/320.1 435/325 435/331 435/69.1 435/7.2 530/387.3 530/391.9

Family:

Publication number	Publication date	Application number	Application date	
AU2014337367 AA	20160407	AU20140337367	20141015	
AU2014337385 AA	20160407	AU20140337385	20141015	
AU2015269210 AA	20161208	AU20150269210	20150605	
AU2015269210 AH	20170105	AU20150269210	20150605	
CA2926698 AA	20160406	CA20142926698	20141015	
CA2927543 AA	20160414	CA20142927543	20141015	
CA2950178 AA	20161123	CA20152950178	20150605	
CN105814083 A	20160727	CN201480064779	20141015	
CN105829349 A	20160803	CN201480066872	20141015	
CN106661128 A	20170510	CN201580042157	20150605	
DE602014046575 D1	20190529	DE201460046575T	20141015	
EP3057991 A1	20160824	EP20140853242	20141015	
EP3057991 A4	20170726	EP20140853242	20141015	
EP3057991 B1	20190508	EP20140853242	20141015	
EP3057991 B8	20190904	EP20140853242	20141015	
EP3057994 A1	20160824	EP20140854285	20141015	
EP3057994 A4	20171025	EP20140854285	20141015	
EP3152238 A1	20170412	EP20150803905	20150605	
EP3152238 A4	20180103	EP20150803905	20150605	
EP3155018 A1	20170419	EP20150803027	20150605	
EP3155018 A4	20180110	EP20150803027	20150605	
ES2741308 T3	20200210	ES20140853242T	20141015	
HK1226750 A1	20171006	HK20170100358	20170111	
HK1226751 A1	20171006	HK20170100359	20170111	
JP2016533174 A2	20161027	JP20160522782	20141015	
JP2016533174 T2	20161027	JP20160522782T	20141015	
JP2016534995 T2	20161110	JP20160522791T	20141015	
JP2017518049 T2	20170706	JP20160569796T	20150605	
JP2020015760 A2	20200130	JP20190186117	20191009	
JP6637415 B2	20200129	JP20160522791T	20141015	
KR20160062760 A	20160602	KR20167012414	20141015	
KR20160062761 A	20160602	KR20167012417	20141015	
KR20170010893 A	20170201	KR20177000273	20150605	
US2015238631 AA	20150827	US20140432065	20141015	
US2015307564 AA	20151029	US20150688894	20150416	
US2017210818 AA	20170727	US20150315641	20150605	
US2017246270 AA	20170831	US20170448477	20170302	
US2017327577 AA	20171116	US20150315645	20150605	
US2018104354 AA	20180419	US20170644657	20170707	
US9624276 BB	20170418	US20150688894	20150416	
US10391155 BB	20190827	US20170448477	20170302	
WO15057834 A1	20150423	WO2014US60684	20141015	
WO15057852 A1	20150423	WO2014US60713	20141015	
WO15188132 A1	20151210	WO2015US34533	20150605	

WO15188132 A8	20170112	WO2015US34533	20150605
WO15188135 A1	20151210	WO2015US34541	20150605

Priority:

US20130891347P 20131015	US20130895704P 20131025	US20140009054P 20140606
US20140009056P 20140606	US20140030526P 20140729	US20140030514P 20140729
EP20140853242 20141015	JP20160522791T 20141015	US20140432065 20141015
US20140064186P 20141015	US20140064199P 20141015	WO2014US60713 20141015
WO2014US60684 20141015	US20150432065 20150327	US20150688894 20150416
US20150315641 20150605	US20150315645 20150605	WO2015US34533 20150605
WO2015US34541 20150605	US20160363350 20161129	US20170448477 20170302
US20170644657 20170707	JP20190186117 20191009	

Probable Assignee: SCRIPPS RESEARCH INST

Assignee(s): (std): CAO YU ; KIM CHANHYUK ; KIM MINSOO ; PINKERTON STEPHANIE A ; MA JENNIFER ; CALIFORNIA INST BIOMEDICAL RES ; CALIFORNIA INST FOR BIOMEDICAL RES ; SCRIPPS RESEARCH INST ; SCHULTZ PETER G ; YOUNG TRAVIS ; SCRIPPS RES INST

Assignee(s): SCRIPPS RESEARCH INST LA JOLLA ; WANG YING ; WANG FENG ; CALIFORNIA INST FOR BIOMEDICAL RESEARCH ; CALIFORNIA INST FOR BIOMEDICAL RESEARCH LA JOLLA ; PINKERTON STEPHANIE ; LIU YAN ; FU GUANGSEN

Inventor(s): (std): SCHULTZ PETER G ; YOUNG TRAVIS ; KIM CHANHYUK ; KIM MINSOO ; CAO YU ; MA JENNIFER ; PINKERTON STEPHANIE ; PINKERTON STEPHANIE A ; LIU YAN ; FU GUANGSEN ; WANG FENG ; DU JUANJUAN ; WANG YING ; KIM CHAN HYUK ; SCHULTZ PETER

Inventor(s): TRAVIS YOUNG ; JENNIFER MA ; STEPHANIE PINKERTON ; PETER G SCHULTZ ; KIM CHANHYUK SAN DIEGO ; YOUNG TRAVIS LA JOLLA ; CAO YU SAN DIEGO ; MA JENNIFER LA JOLLA ; KIM MINSOO SAN DIEGO ; PINKERTON STEPHANIE SAN DIEGO ; SCHULTZ PETER G LA JOLLA

Agent(s): DAVIES COLLISON CAVE; DAVIES COLLISON CAVE PTY LTD; SPRUSON AND FERGUSON; BORDEN LADNER GERVAIS LLP; GOWLING WLG CANADA LLP; SCHIWECK WEINZIERL AND KOCH; SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBB; CARPMAELS AND RANSFORD LLP; JUAN ARIAS ARIAS; INSIGHT HK INTELLECTUAL PROPERTY LTD; COOLEY LLP; HARDT INGO H

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

2) Family number: 61255102 (US2016030585A)

© PatBase

Title: NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES

Abstract:

The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Classifications:

International (IPC 8-9): A61K

A61K31/20 A61K31/4192

A61K38/08 A61K38/16

A61K38/17 A61K38/18

A61K38/19 A61K38/22 A61K45/00 A61K45/06 A61K47/12 A61K47/16 A61K47/22 A61K47/34

A61K47/44 A61K47/48 A61K47/50 A61K47/54 A61P A61P1/00 A61P1/04 A61P1/16 A61P1/18

A61P13/12 A61P25/18 A61P3/00 A61P3/04 A61P3/06 A61P3/10 A61P5/48 A61P5/50 A61P9/00

A61P9/04 A61P9/10 A61P9/12 A61P9/14 C07C233/13 C07C55/02 C07C55/22 C07C57/02 C07C57/18

C07C57/22 C07C59/245 C07C59/42 C07D249/16 C07K C07K14/475 C07K14/525 C07K7/00

C12N15/113 (Advanced/Invention);

A61P3/00 (Core/Invention);

A61K A61P C07K (Subclass/Invention)

International (IPC 1-7): A61K47/48 A61P3/00 C07K14/475

CPC: A61K47/48038 C12N15/113 C12N2310/14 C12N2310/351 A61K38/08 A61K38/164

A61K38/1709 A61K38/1825 A61K38/1841 A61K38/2221 A61K47/542 A61K45/06 A61K47/543

C07C55/02 C07C55/22 C07C57/02 C07C57/18 C07C59/245 A61P1/00 A61P1/04 A61P1/16 A61P1/18

A61P3/00 A61P3/04 A61P25/18 A61P3/06 A61P3/10 A61P5/48 A61P5/50 A61P9/00 A61P9/04

A61P9/10 A61P9/12 A61P9/14


US: 1/1 514/1.9 514/11.7 514/4.8 514/44A 514/6.5 514/6.7 514/6.9 514/7.4 514/8.9 530/315

530/350 530/399 536/24.5 554/121 554/122

Family:

Publication number	Publication date	Application number	Application date
AP201609585 A0	20161130	AP20160009585	20150618
AR100939 AA	20161109	AR2015P101998	20150623
AU2015280351 AA	20161208	AU20150280351	20150618
AU2015280351 BB	20180705	AU20150280351	20150618
BR112016028884 A2	20171031	BR20161128884	20150618
CA2953480 AA	20161222	CA20152953480	20150618
CL2016003281 A1	20170609	CL20160003281	20161221

PatBase - US2016030585 AA



CN107073130 A	20170818	CN201580033910	20150618
CO20160005665 A2	20170310	CO20160005665	20161221
CR20160596 A	20170508	CR20160000596	20150618
CU20160189 A7	20170405	CU20160000189	20161222
CU24455 B	20191104	CU20160000189	20161222
EA201692466 A1	20170428	EA20160092466	20150618
EP3157571 A1	20170426	EP20150732508	20150618
GT201600263 A	20190719	GT20160000263	20161222
HK1232160 A1	20180105	HK20170105974	20170615
ID201710716 A	20170929	ID2016P0008318	20150618
IL248990 A0	20170131	IL20150248990	20150618
IL248990 A1	20190926	IL20150248990	20150618
IN201617040617 A	20170331	IN201617040617	20161128
JP2017519024 T2	20170713	JP20160574916T	20150618
JP2019206563 A2	20191205	JP20190140962	20190731
JP6636959 B2	20200129	JP20160574916T	20150618
KR20170020878 A	20170224	KR20177001520	20150618
MX2016017395 A1	20170501	MX20160017395	20150618
MX367520 B	20190826	MX20160017395	20150618
PE10952017 A1	20170807	PE20160002771	20150618
PE20171095 A1	20170807	PE20160002771	20150618
PH2016502294 A	20170213	PH20160502294	20161117
SG10201912965T A1	20200227	SG20191012965	20150618
SG11201609704T A1	20170127	SG20161109704	20150618
TN2016000558 A1	20180404	TN20160000558	20150618
TW201613653 A	20160416	TW20150120074	20150622
US2016030585 AA	20160204	US20150738272	20150612
US2018326079 AA	20181115	US20180985060	20180521
US10588980 BB	20200317	US20150738272	20150612
UY36186 A1	20160129	UY20150036186	20150622
WO15200078 A1	20151230	WO2015US36328	20150618
WO15200078 A8	20160414	WO2015US36328	20150618

Priority:

US20140015862P 20140623	US20140082327P 20141120	US20150107016P 20150123
US20150738272 20150612	JP20160574916T 20150618	WO2015US36328 20150618
US20180985060 20180521	JP20190140962 20190731	

Probable Assignee: NOVARTIS AG

Assignee(s): (std): BARNES DAVID WENINGER ; BOSE AVIRUP ; BRUCE ALEXANDRA MARSHALL ; DUTTARROY ALOKESH ; KIRMAN LOUISE CLARE ; NOVARTIS AG ; LOU CHANGGANG ; KANTER AARON ; IBEUNJO CHIKWENDU ; KIRMAN LOUIS CLARE ; NOVARTIS INT AG ; YUAN JUN ; USERA AIMEE RICHARDSON ; ZECRI FREDERIC ; YAMADA KEN

Assignee(s): NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC

Inventor(s): (std): LOU CHANGGANG ; BOSE AVIRUP ; BRUCE ALEXANDRA MARSHALL ; KIRMAN LOUISE CLARE ; YAMADA KEN ; BARNES DAVID WENINGER ; DUTTARROY ALOKESH ; ZECRI FREDERIC ; YUAN JUN ; USERA AIMEE RICHARDSON ; IBEUNJO CHIKWENDU ; KANTER AARON ; KIRMAN LOUIS CLARE ; CHANGGANG LOU ; AARON KANTER ; CHIKWENDU IBEUNJO ; AVIRUP BOSE ; KEN YAMADA ; ALOKESH DUTTARROY ; DAVID WENINGER BARNES ; ALEXANDRA MARSHALL BRUCE ; FREDERIC ZECRI ; LOUISE CLARE KIRMAN ; AIMEE

RICHARDSON USERA ; LOU CHANG GANG ; JUN YUAN ; FRDRIC ZECRI ;
YAMADA TAKESHI ; ALOKESH DURRARROY

Inventor(s): 1 BARNES DAVID WENINGER ; 2 YAMADA KEN ; 3 IBEBUNJO CHIKWENDU ; 4
DUTTARROY ALOKESH ; 5 KIRMAN LOUISE CLARE ; 6 BRUCE ALEXANDRA
MARSHALL ; 7 USERA AIMEE RICHARDSON ; 8 ZECRI FREDERIC ; 9 YUAN JUN ;
10 LOU CHANGGANG ; 11 KANTER AARON ; 12 BOSE AVIRUP

Agent(s): DAVIES COLLISON CAVE PTY LTD; FETHERSTONHAUGH AND CO; RODRIGO
JAVIER MARRE GREZ; CARLOS REINALDO OLARTE GARCIA; WOODCOCK
BOURNE HEATHER; MARKS AND CLERK; BUDI RAHMAT SH; LUZZATTO AND
LUZZATTO; KATAYAMA EIJI; OHMORI NORIO; KOBAYASHI HIROSHI; DREW AND
NAPIER LLC; KUNTZ JUDITH D; MARSHALL RYAN L

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG
CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB
GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN
KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT
MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW
SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA
UG US UZ VC VN ZA ZM ZW

3) Family number: 43222152 (US2011098217A)

© PatBase

Title: COMPOUNDS EXHIBITING GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY

Abstract:

Glucagon analogs are disclosed that exhibit both glucagon antagonist and GLP-1 agonist activity. In one embodiment, the glucagon antagonist/GLP-1 agonist comprises a modified amino acid sequence of native glucagon, in which the first one to five N-terminal amino acids of native glucagon is deleted and in which the alpha helix is stabilized.

Classifications:

International (IPC 8-9): A61K

A61K38/00 A61K38/16

A61K38/22 A61K38/26

A61K39/00 A61K47/48

A61P1/00 A61P13/12

A61P19/00 A61P21/00

A61P27/02 A61P3/04 A61P3/06

A61P3/10 A61P38/00

A61P43/00 A61P9/00 A61P9/10

A61P9/12 C07K C07K14/00

C07K14/435 C07K14/605

C07K7/02

C07K7/64 (Advanced/Invention);

A61K38/00 A61P3/10 (Advanced/Non-invention);

A61K38/00 A61K38/26 A61K39/00 A61P3/00 C07K14/435 (Core/Invention);

A61K C07K (Subclass/Invention)

International (IPC 1-7): A61K38/26 A61P3/10 C07K14/435 C07K14/605

CPC: A61K38/00 C07K14/605 A61K38/16 A61K38/22 A61K38/26 C07K7/02 A61P1/00 A61P13/12


A61P19/00 A61P21/00 A61P3/04 A61P27/02 A61P3/06 A61P3/10 A61P9/00 A61P9/10 A61P9/12

A61P43/00

European: C07K14/605 K61K38/00

US: 514/21.3 514/21.300S 514/4.9 514/4.900P 514/6.9 514/6.900S 530/308 530/323 530/324

530/324S 530/326 530/326S



Family:

Publication number	Publication date	Application number	Application date
AR069136 AA	20091230	AR2008P104771	20081030
AU2008318876 AA	20090507	AU20080318876	20081027
AU2008318876 BB	20140515	AU20080318876	20081027
CA2702289 AA	20090507	CA20082702289	20081027
CL2008003243 A1	20090227	CL20080003243	20081030
DE602008040447 D1	20151112	DE200860040447T	20081027
EP2214691 A1	20100811	EP20080845541	20081027
EP2214691 A4	20110105	EP20080845541	20081027
EP2214691 B1	20150930	EP20080845541	20081027
ES2558155 T3	20160202	ES20080845541T	20081027
HK1141984 A1	20160318	HK20100108381	20100903
HK1141984 A1	20101126	HK20100108381	20100903
HK1141984 B	20160318	HK20100108381	20100903
JP2011502159 T2	20110120	JP20100532174T	20081027
JP5771005 B2	20150826	JP20100532174T	20081027
MX2010004298 A1	20100503	MX20100004298	20081027
PA8802301 A1	20090623	PA20080088023	20081030
PE09322009 A1	20090715	PE20080001855	20081030
PE20090932 A1	20090715	PE20080001855	20081030
TW200920395 A	20090516	TW20080141893	20081030
US2011098217 AA	20110428	US20080740206	20081027
US8980830 BB	20150317	US20080740206	20081027
WO09058734 A1	20090507	WO2008US81333	20081027
WO09058734 A4	20090723	WO2008US81333	20081027

Priority:

US20070983766P 20071030 US20080090441P 20080820 EP20080845541 20081027
WO2008US81333 20081027 US20080740206 20081027

Probable Assignee: UNIV INDIANA RES AND TECH CORP

Assignee(s): (std): DIMARCHI RICHARD D ; INDIANA UNIV RES AND TECH CORP ; INDIANA UNIV RESEARCH AND TECHNOLOGY CORP ; OUYANG CHENGUANG ; YANG BIN ; UNIV INDIANA RES AND TECH CORP

Assignee(s): INDIANA UNIV RESEARCH AND TECHNOLOGY CORPORA ; INDIANA UNIV RESEARCH AND TECHNOLOGY INDIANAPOLIS CORP

Inventor(s): (std): DIMARCHINI RICHARD ; DIMARCHI RICHARD ; CHENGUANG OUYANG ; BIN YANG ; RICHARD DIMARCHI ; OUYANG CHENGUANG ; YANG BIN ; DIMARCHI RICHARD D

Inventor(s): RICHARD D DIMARCHI ; OUYANG CHENGUANG BLOOMINGTON


Agent(s): SPRUSON AND FERGUSON; TRANSGLOBO; SCHOPPE ZIMMERMANN
STOECKELER ZINKLER SCHENK AND PARTNER MBB PATENTANWALTE; PONTI
SALES ADELAIDA; OFICINA PONTI SLP; PONTI ADELAIDA; WENPING AND CO;
ISSHIKI AND CO; BARNES AND THORNBURG LLP; ADDISON BRADFORD G

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI
CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH
GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA
LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ
NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN
ST SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: COMPOSITION FOR TREATING DIABETES MELLITUS COMPRISING INSULIN AND A GLP-1/ GLUCAGON DUAL AGONIST

Abstract:
A composition for preventing or treating diabetes mellitus includes insulin and a GLP-1/glucagon dual agonist. The composition can inhibit the weight gain and reduce the danger of hypoglycemia due to the administration of insulin, lower the administration dose and greatly improve the compliance of drugs through a combined administration of a long-acting insulin conjugate and a long-acting GLP-1/glucagon dual agonist conjugate. In addition, the long-acting insulin conjugate and the long-acting GLP-1/glucagon dual agonist conjugate can improve the in vivo sustainability and stability because an insulin and a GLP-1/glucagon dual agonist are linked to the immunoglobulin Fc region via a non-peptidyl linker. A method for preventing or treat diabetes mellitus includes administration of the insulin and a GLP-1/glucagon dual agonist.

Classifications:
International (IPC 8-9): A61K A61K38/22 A61K38/26 A61K38/28 A61K45/00 A61K47/10 A61K47/12 A61K47/28 A61K47/30 A61K47/32 A61K47/36 A61K47/42 A61K47/46 A61K47/48 A61K47/50 A61K47/60 A61K47/68 A61K9/20 A61P A61P3/00 A61P3/10 C07K14/575 C07K14/605 C07K14/62 C07K14/72 C07K16/46 C07K19/00 (Advanced/Invention)
International (IPC 1-7): A61K38/26 A61K38/28 A61P3/00 A61P3/10
CPC: A61K47/30 A61K9/20 A61K2300/00 A61K47/48 A61K47/48369 A61K47/48215 A61K38/26 A61K38/28 A61K47/60 A61K47/68 A61K47/50 A61K47/6811 A61K47/6889 C07K2319/30 C07K2319/00 C07K16/46 C07K19/00 C07K2317/52 C07K2317/53 A61P3/00 A61P3/10
US: 1/1 424/179.1



Family:

Publication number	Publication date	Application number	Application date
AR100695 AA	20161026	AR2015P101721	20150529
AU2015268199 AA	20170112	AU20150268199	20150601
BR112016028076 A2	20171024	BR20161128076	20150601
CA2950718 AA	20161129	CA20152950718	20150601
CL2016003069 A1	20170512	CL20160003069	20161129
CN106604739 A	20170426	CN201580040542	20150601
EA201692282 A1	20171031	EA20160092282	20150601
EP3148571 A1	20170405	EP20150799077	20150601
EP3148571 A4	20171220	EP20150799077	20150601
HK1235013 A1	20180302	HK20170108847	20170901

ID201712266 A	20171110	ID2016P0008768	20150601
IL249264 A0	20170228	IL20150249264	20150601
IL249264 A1	20190926	IL20150249264	20150601
IN201617041247 A	20170303	IN201617041247	20161202
JP2017518298 T2	20170706	JP20160570276T	20150601
KR20150138119 A	20151209	KR20150077271	20150601
MX2016015669 A1	20170227	MX20160015669	20150601
PE00872017 A1	20170309	PE20160002496	20150601
PE20170087 A1	20170309	PE20160002496	20150601
PH2016502390 A	20170220	PH20160502390	20161129
SG11201609872Y A1	20161229	SG20161109872	20150601
TW201625292 A	20160716	TW20150117391	20150529
TWI684458 B	20200211	TW20150117391	20150529
US2017196943 AA	20170713	US20150315020	20150601
US10188703 BB	20190129	US20150315020	20150601
WO15183054 A1	20151203	WO2015KR05455	20150601
ZA201608764 A	20170726	ZA20160008764	20161220

Priority:

KR20140066554 20140530 KR20150077271 20150601 WO2015KR05455 20150601

Probable Assignee: HANMI PHARM IND CO LTD

Assignee(s): (std): HANMI PHARM CO LTD ; HANMI PHARM IND CO LTD ; KIM SEUNG SU ; HWANG SANG YOUN ; KWON SE CHANG ; JUNG SUNG YOUB ; HANMI PHARMACEUTICAL CO LTD ; CHOI IN YOUNG

Assignee(s): HANMI PHARM CO

Inventor(s): (std): KIM SEUNG SU ; KWON SE CHANG ; JUNG SUNG YOUB ; HWANG SANG YOUN ; CHOI IN YOUNG ; CHANG KWON SE ; YOUB JUNG SUNG ; YOUNG CHOI IN ; YOUN HWANG SANG ; SU KIM SEUNG ; SUNG YOUB JUNG ; SANG YOUN HWANG ; SEUNG SU KIM ; IN YOUNG CHOI ; SE CHANG KWON

Inventor(s): KWON SE CHAN

Agent(s): FB RICE; FB RICE PTY LTD; BERESKIN AND PARR LLP SENCRL SRL; ESTUDIO CAREY LTDA; ANDREWS ROBERT; ORIENTAL INTELLECTUAL PROPERTY SERVICES CO; ADOLF MARTUA PANGGABEAN MAROLITA SETIATI; BEN AMI AND ASSOCIATES; YAMASAKI KAZUO; NISHIJIMA TAKAKI; HAKODA ATSUSHI; HATTORI HIRONOBU; ICHIKAWA SATSUKI; ASAI KENJI; DESHIMARU TAKESHI; SUGHRUE MION PLLC; SON MIN

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

5) Family number: 58512185 (US2016185837A)

© PatBase

Title: GIP AND GLP-1 RECEPTOR DUAL-AGONISTS FOR THE TREATMENT OF DIABETES

Abstract:

This disclosure provides GIP/GLP-1 dual agonist polypeptides for the treatment of hypoglycemic conditions, e.g., type-2 diabetes.

Classifications:**International (IPC 8-9):**

A61K38/22 A61K38/26
A61K39/395 A61K45/06
A61K9/00 C07K C07K14/575
C07K14/605 C07K14/645
C07K16/26 C12N
C12N15/62 (Advanced/Invention)

CPC: C07K14/57563

C07K14/605 C07K2319/30
A61K9/0019 A61K38/2235
A61K38/26 A61K39/3955
A61K45/06 A61K2039/505
A61K2039/54 C07K14/645
C07K16/26 C07K2317/524
C07K2317/526 C07K2317/71
C07K2317/75 C07K2317/94

US: 424/134.1 435/252.33

435/254.2 435/254.21

435/254.23 435/320.1 435/328

435/348 435/357 435/358

435/360 435/365 435/365.1

435/369 435/69.4 435/69.6 514/5.3 514/6.5 514/7.2 530/308 530/387.3 536/23.4 536/23.51

PatBase - US2016185837 AA




FIG. 1

Family:

Publication number	Publication date	Application number	Application date
EP3033355 A1	20160622	EP20140752848	20140815
HK1226084 A1	20170922	HK20160114399	20161219
US2016185837 AA	20160630	US20140911910	20140815
WO15022420 A1	20150219	WO2014EP67479	20140815

Priority:

US20130866791P 20130816

US20140911910 20140815

WO2014EP67479 20140815

Probable Assignee: MEDIMMUNE LTD

Assignee(s): (std): MEDIMMUNE LTD

Assignee(s): MEDIMMUNE LTD

Inventor(s): (std): RAVN PETER ; COLLINSON ANDIE ; HORNIGOLD DAVID ; PAPWORTH MONIKA ; SERMADIRAS ISABELLE ; BEDNAREK MARIA ; O BRIEN SIOBHAN

Agent(s): TTOFI EVANGELIA; CHINA PATENT AGENT HK LTD

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

Title: GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY

Abstract:

Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet other embodiments, the peptide combination is provided as a conjugate, e.g., a fusion peptide, a heterodimer. In specific aspects, the GIP agonist peptide is an analog of native human glucagon. In specific aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the peptide compositions described herein are further provided.

Classifications:

International (IPC 8-9): A61K

A61K38/00 A61K38/16

A61K38/26 A61K39/395

A61K47/48 A61P1/00

A61P25/02 A61P3/00 A61P3/04

A61P3/10 A61P43/00 A61P5/50

C07K14/00 C07K14/605

C07K14/705 C07K19/00

C07K7/06

C07K7/08 (Advanced/Invention)

CPC: A61K2300/00 A61P3/00

A61P3/04 A61P25/02

A61K47/50 A61K47/59

A61K38/26 C07K14/605 A61P3/10 A61P5/50 A61P43/00


European: A61K38/26 C07K14/605

US: 1/1 514/1.1 514/21.3 514/4.8 514/5.3 514/6.7 514/6.8 514/6.9 514/7.2 530/308 530/324

530/325 530/350

Family:

Publication number	Publication date	Application number	Application date
BR112012018585 A2	20170110	BR20121118585	20110126
CA2788304 AA	20110804	CA20112788304	20110126
CN102834108 A	20121219	CN201180017089	20110126
EP2528618 A1	20121205	EP20110737598	20110126
EP2528618 A4	20150527	EP20110737598	20110126
HK1179856 A1	20131011	HK20130107067	20130617
IN06437DN2012 A	20151009	IN2012DN06437	20120720
JP2013518115 T2	20130520	JP20120551270T	20110126
JP2016183177 A2	20161020	JP20160100832	20160519
KR20120123443 A	20121108	KR20127021672	20110126



MX2012008603 A1	20130125	MX2012008603	20110126	
RU2012136450 A	20140310	RU20120136450	20110126	
US2012322725 AA	20121220	US20110575363	20110126	
US2014107021 AA	20140417	US20130026671	20130913	
US8551946 BB	20131008	US20110575363	20110126	
US9487571 BB	20161108	US20130026671	20130913	
WO11094337 A1	20110804	WO2011US22608	20110126	
WO11094337 A8	20120816	WO2011US22608	20110126	

Priority:

US20100298812P 20100127 JP20120551270T 20110126 US20110575363 20110126
WO2011US22608 20110126 US20120575363 20120726 US20130026671 20130913
JP20160100832 20160519

Probable Assignee: INDIANA UNIV RESEARCH AND TECHNOLOGY CORP

Assignee(s): (std): DIMARCHI RICHARD D ; INDIANA UNIV RES AND TECH CORP ; MA TAO ; UNIV INDIANA RES AND TECH CORP ; MAT TAO

Assignee(s): INDIANA UNIV RESEARCH AND TECHNOLOGY CORP

Inventor(s): (std): TAO MA ; MA TAO ; MAT TAO ; DIMARCHI RICHARD D ; TAO MAT

Inventor(s): RICHARD D DIMARCHI

Agent(s): SMART AND BIGGAR; PONTI SALES ADELAIDA; CHINA PATENT AGENT HK LTD; ISSHIKI AND CO; BARNES AND THORNBURG LLP; BREEN JOHN P

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

7) Family number: 42109634 (US2010190701A)

© PatBase

Title: GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS

Abstract:

Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (K-RNRNNIA) and SEQ ID NO: 28 (KRNR).

Classifications:

International (IPC 8-9): A61K

A61K38/00 A61K38/26

A61K47/48 A61P1/00

A61P21/00 A61P3/04 A61P3/06

A61P3/08 A61P3/10 A61P9/00

A61P9/10 A61P9/12 C07K

C07K14/415 C07K14/43

C07K14/605 C07K16/00

C07K19/00 (Advanced/Invention);

A61K38/00 (Advanced/Non-

invention);

A61K38/26 A61K47/48

A61P3/00 C07K14/415

C07K14/435 (Core/Invention);

A61K C07K (Subclass/Invention)

International (IPC 1-7):

A61K38/26 A61P3/04 A61P3/10

C07K14/605

CPC: C07K19/00 A61K38/00

A61K38/26 A61K47/60

C07K14/605 C07K16/00 C07K2317/52 C07K2319/30 A61P1/00 A61P21/00 A61P3/04 A61P3/06

A61P3/08 A61P3/10 A61P9/00 A61P9/10 A61P9/12

European: C07K14/605 K61K38/00


US: 1/1 424/198.1 514/1.1 514/11.7 514/12 514/5.3 514/7.2 530/308 530/387.3 530/399

Family:

Publication number	Publication date	Application number	Application date
AR065349 AA	20090603	AR2008P100632	20080214
AR080904 AB	20120516	AR2011P101281	20110414
AU2008216265 AA	20080821	AU20080216265	20080213
AU2008216265 BB	20140403	AU20080216265	20080213
AU2013204126 AA	20130502	AU20130204126	20130412
BRPI0807728 A2	20120417	BR2008PI07728	20080213
CA2677932 AA	20090811	CA20082677932	20080213
CL2008000479 A1	20080822	CL20080000479	20080214
CL51873 B	20160203	CL20080000479	20080214
CN101790538 A	20100728	CN200880012086	20080213
CN101790538 B	20140730	CN200880012086	20080213

PatBase - US2010190701 AA

Parent Application Publication Jul. 29, 2010 Sheet 1 of 24 US 2010/0190701 A1



CR11028 A	20091029	CR20090011028	20090914	
DE602008033093 D1	20140814	DE200860033093T	20080213	
DOP2009000194 A	20100630	DO20090000194	20090730	
EA017849 B1	20130329	EA20090001108	20080213	
EA200901108 A1	20100226	EA20090001108	20080213	
ECSP099622 A	20091030	EC2009SP09622	20090910	
EP2111414 A2	20091028	EP20080729769	20080213	
EP2111414 B1	20140702	EP20080729769	20080213	
EP2487184 A1	20120815	EP20110196006	20080213	
GT200900229 A	20110121	GT20090000229	20090813	
HK1135993 A1	20140919	HK20100102425	20100308	
HK1135993 A1	20100618	HK20100102425	20100308	
HK1135993 B	20140919	HK20100102425	20100308	
HN2009001593 A	20120813	HN20090001593	20090813	
IL200396 A0	20100429	IL20080200396	20080213	
IL200396 A1	20160229	IL20080200396	20080213	
IN05128DN2009 A	20100319	IN2009DN05128	20090807	
JP2011511753 T2	20110414	JP20090549703T	20080213	
JP2014141500 A2	20140807	JP20140043047	20140305	
JP6017754 B2	20161102	JP20090549703T	20080213	
KR20090119876 A	20091120	KR20097018548	20080213	
KR20150116465 A	20151015	KR20157026403	20080213	
MA31242 B1	20100301	MA20090032206	20090907	
MX2009008241 A1	20091008	MX20090008241	20080213	
NZ578948 A	20120330	NZ20080578948	20080213	
PA8769301 A1	20081218	PA20080087693	20080214	
PE01082009 A1	20090215	PE20080000317	20080214	
PE01592014 A1	20140208	PE20130000081	20080214	
PE20090108 A1	20090215	PE20080000317	20080214	
PE20140159 A1	20140208	PE20130000081	20080214	
TH151166 A	20160510	TH20081000736	20080214	
TN2009000313 A1	20101231	TN20090000313	20090730	
TW200848423 A	20081216	TW20080105251	20080214	
TWI547499 B	20160901	TW20080105251	20080214	
UA104842 C2	20140325	UA20090009473	20080213	
US2010190701 AA	20100729	US20080527140	20080213	
US2013203660 AA	20130808	US20130737232	20130109	
US2015126440 AA	20150507	US20140535853	20141107	
US8454971 BB	20130604	US20080527140	20080213	
US8900593 BB	20141202	US20130737232	20130109	
US9447162 BB	20160920	US20140535853	20141107	
WO08101017 A2	20080821	WO2008US53857	20080213	
WO08101017 A3	20081218	WO2008US53857	20080213	
ZA200905521 A	20111026	ZA20090005521	20090806	

Priority:

US20070890087P 20070215	US20070938565P 20070517	AU20080216265 20080213
EP20080729769 20080213	JP20090549703 20080213	JP20090549703T 20080213
WO2008US53857 20080213	US20080527140 20080213	US20100527140 20100301
US20130737232 20130109	AU20130204126 20130412	US20140535853 20141107

Probable Assignee: INDIANA UNIV RESEARCH AND TECHNOLOGY CORPORA

Assignee(s): (std): CHABENNE JOSEPH ; DAY JONATHAN ; DIMARCHI MARIA ; DIMARCHI RICHARD D ; INDIANA UNIVERSITY RES AND TECH ; SMILEY DAVID ; INDIANA UNIVERSITY RES AND TECH ; PATTERSON JAMES ; SMILEY DAVID ; INDIANA UNIVERSITY RES AND TECHNOLOGY CORP ; TION INDIANA UNIV RES AND TECHNOLOGY CORPORA ; INDIANA UNIV RES AND TECH CORP ; SMILEY DAVID L ; INDIANA UNIV RES AND TECHNOLOGY CORP ; UNIV INDIANA RES AND TECH CORP

Assignee(s): INDIANA UNIV RESEARCH AND TECHNOLOGY CORP INDIANAPOLIS ; INDIANA UNIV RESEARCH AND TECHNOLOGY CORP ; INDIANA UNIV RESEARCH AND TECHNOLOGY CORPORA ; INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP ; TION INDIANA UNIV RESEARCH AND TECHNOLOGY CORPORA ; INDIANA UNIV RESEARCH AND TECHNOLOGY CORP ; INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP

Inventor(s): (std): JONATHAN DAY JAMES PATTERSON J ; MARIA DIMARCHI ; JONATHAN DAY ; DAVID SMILEY ; JOSEPH CHABENNE ; JAMES PATTERSON ; RICHARD DIMARCHI ; DIMARCHI RICHARD ; SMILEY DAVID ; DAY JONATHAN ; DIMARCHI MARIA ; DIMARCHI RICHARD D ; CHABENNE JOSEPH ; PATTERSON JAMES ; RICHARD D DIMARCHI ; DIMARCHI RICHARD DENNIS ; SMILEY DAVID LEE ; PETERSON JAMES ; DAY JOHATHAN ; SMILEY DAVID L ; JOSEP CHABENNE ; DAVID DMILEY ; DIMARCHI DAVID ; SMILEY DAVID ; DIMARCH MARIA

Inventor(s): JOHATHAN DAY ; JAMES PETTERSON ; MARIA DIMARCH ; SMILEY DAVID BLOOMINGTON ; DIMARCHI RICHARD D CARMEL ; DAY JONATHAN BLOOMINGTON ; CHABENNE JOSEPH FISHERS ; DIMARCHI MARIA CARMEL ; PATTERSON JAMES MARTINSVILLE ; JONATHAN DAY JAMES PATTERSON JOSEPH CHABENNE MARIA DIMARCHI DAVID SMILEY RICHARD DIMARCHI ; NA ; JONATHAN DAY JAMES PATTERSON JOSEPH CHABENNE ; SMILEY DAVID AND

Agent(s): SPRUSON AND FERGUSON; SMART AND BIGGAR; TRANSGLOBO; PONTI SALES ADELAIDA; OFICINA PONTI SLP; WENPING AND CO; DR SHLOMO COHEN AND CO; ISSHIKI AND CO; BARNES AND THORNBURG LLP; ADDISON BRADFORD G

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

8) Family number: 58395764 (US2015030594A)

© PatBase

Title: BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES

Abstract:

The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I' (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Classifications:

International (IPC 8-9): A61K A61K38/00 A61K38/10 A61K38/12 A61K38/17 A61K39/395 A61K45/00 A61K45/06 A61K47/42 A61K47/44 A61K47/48 A61K47/54 A61K47/62 A61K47/64 A61K47/68 A61P17/02 A61P17/16 A61P21/02 A61P25/00 A61P3/04 A61P3/10 A61P43/00 A61P7/00

PatBase - W015013169 A9
X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (I)

A61P9/00 A61P9/04 A61P9/06 A61P9/10 A61P9/12 C07K14/47 C07K14/76 C07K14/765 C07K16/00 C07K16/46 C07K19/00 C07K7/08 C07K7/50 C07K7/64 (Advanced/Invention);
A61K (Subclass/Invention)
International (IPC 1-7): A61K47/48
CPC: A61K38/00 A61K45/06 A61K47/542 A61K47/643 A61K47/68 A61K47/6811 C07K14/47 C07K14/765 C07K2319/30 C07K2319/31 A61K38/10 A61P17/02 A61P17/16 A61P21/02 A61P25/00 A61P3/04 A61P3/10 A61P7/00 A61P9/00 A61P9/04 A61P9/06 A61P9/10 A61P9/12 A61P43/00
US: 1/1 424/134.1 424/179.1 514/1.9 514/15.1 514/15.7 514/16.4 514/17.7 514/18.6 514/21.1 514/21.5 514/4.8 514/6.9 530/321 530/327 530/363 530/387.3 530/391.1

Family:

Publication number	Publication date	Application number	Application date
AP201609019 A0	20160229	AP20160009019	20140721
AU2014293387 AA	20160211	AU20140293387	20140721
AU2014293387 BB	20170420	AU20140293387	20140721
BR112016001376 A2	20171024	BR20161101376	20140721
CA2918077 AA	20160112	CA20142918077	20140721
CL2016000157 A1	20160708	CL20160000157	20160121
CN105705167 A	20160622	CN201480052603	20140721
CO16025039 A2	20160620	CO20160025039	20160203
CR20160049 A	20160617	CR20160000049	20160125
CU20160012 A7	20160831	CU20160000012	20160125
EA201690282 A1	20160930	EA20160090282	20140721
EP3024492 A2	20160601	EP20140747491	20140721
HK1218252 A1	20170210	HK20160106225	20160601
IL243691 A0	20160421	IL20140243691	20140721
IN201617001981 A	20160812	IN201617001981	20160119
JP2016527249 T2	20160908	JP20160529808T	20140721
KR20160031552 A	20160322	KR20167004513	20140721
MA38866 A2	20181031	MA20140038866	20140721
MA38866 A3	20181130	MA20140038866	20140721
MX2016001021 A1	20160803	MX20160001021	20140721
PE09912016 A1	20161015	PE20160000097	20140721
PE20160991 A1	20161015	PE20160000097	20140721
PH2016500103 A	20160418	PH20160500103	20160115
SG11201600208R A1	20160226	SG20161100208	20140721
TN2016000029 A1	20170705	TN20160000029	20140721
TW201518323 A	20150516	TW20140124997	20140721
US2015030594 AA	20150129	US20140336290	20140721
US2016166634 AA	20160616	US20160053316	20160225
US9340582 BB	20160517	US20140336290	20140721
UY35671 A1	20150227	UY20140035671	20140721
WO15013169 A2	20150129	WO2014US47378	20140721
WO15013169 A3	20150319	WO2014US47378	20140721
WO15013169 A9	20161020	WO2014US47378	20140721

Priority:

US20130858303P 20130725 US20140015848P 20140623 US20140336290 20140721
WO2014US47378 20140721 US20160053316 20160225

Probable Assignee: NOVARTIS AG

Assignee(s): (std): CAPLAN SHARI L ; CAPLAN SHARI LYNN ; GOLOSOV ANDREI ; GROSCHE PHILIPP ; GUIMARAES CARLA ; IRM LLC ; LOU CHANGGANG ; NOVARTIS AG ; PETERS ERIC ; PARKER DAVID THOMAS ; KANTER AARON ; PETERS ERIC C ; NOVARTIS INT AG ; YASOSHIMA KAYO ; YUAN JUN ; ZECRI FREDERIC ; USERA AIMEE RICHARDSON ; ZHAO HONGJUAN ; ZECRI FEDERIC

Assignee(s): NOVARTIS INST FOR FUNCTIONAL GENOMICS INC D B A GENOMICS INST OF NOVARTIS RESEARCH FOUNDATION GNF ; NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC ; NOVARTIS INSTITUTES OF BIOMEDICAL RESEARCH INC ; NOVARTIS PHARMA AG ; NOVARTIS INT PHARMACEUTICAL LTD

Inventor(s): (std): LOU CHANGGANG ; GROSCHE PHILIPP ; PETERS ERIC ; PARKER DAVID THOMAS ; YASOSHIMA KAYO ; YUAN JUN ; GOLOSOV ANDREI ; ZECRI FREDERIC ; CAPLAN SHARI LYNN ; KANTER AARON ; USERA AIMEE RICHARDSON ; GUIMARAES CARLA ; ZHAO HONGJUAN ; PETERS ERIC C ; CAPLAN SHARI L ; JUN YUAN ; ANDREI GOLOSOV ; KAYO YASOSHIMA ; AARON KANTER ; PHILIPP GROSCHE ; HONGJUAN ZHAO ; CARLA GUIMARAES ; CHANGGANG LOU ; FREDERIC ZECRI ; DAVID THOMAS PARKER ; ERIC C PETERS ; AIMEE RICHARDSON USERA ; SHARI L CAPLAN ; LOU CHANG GANG ; ZECRI FEDERIC ; PHILLIPP GROSCHE ; THOMAS PARKER DAVID ; RICHARDSON USERA AIMEE ; GUAIMARAES CARLA

Inventor(s): DAVID THOMAS CHANGGANG ; SHARI LYNN CAPLAN

Agent(s): DAVIES COLLISON CAVE; DAVIES COLLISON CAVE PTY LTD; FETHERSTONHAUGH AND CO; SMART AND BIGGAR IP AGENCY CO; RODRIGO MARRE GREZ; CARLOS REINALDO OLARTE GARCIA; WOODCOCK BOURNE HEATHER; MARKS AND CLERK; KATAYAMA EIJI; OHMORI NORIO; KOBAYASHI HIROSHI; SOPHIE BINET; NOVARTIS AG

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

9) Family number: 55974815 (US2014073563A)

© PatBase

Title: FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME

Abstract:

The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.

Classifications:

International (IPC 8-9): A61K

A61K38/00 A61K38/18

A61K38/22 A61K38/26


A61K47/48 A61K47/60

A61P3/00 A61P3/04 A61P3/06

A61P3/08 A61P3/10 A61P9/00

A61P9/10 C07K C07K14/00

C07K14/50 C07K14/575 C07K14/605 C07K19/00 C12N1/15 C12N1/19 C12N1/21 C12N15/09



C12N15/12 C12N15/16 C12N15/62 C12N15/70 C12N5/10 C12P21/02 (Advanced/Invention);
A61K C07K (Subclass/Invention)

International (IPC 1-7): A61K38/18 A61K38/26 C07K14/50 C07K14/605

CPC: A61K38/00 C07K14/50 C07K14/605 C07K2319/00 A61K38/1825 A61K38/26 A61K47/60
C07K14/57563 C07K2319/30 C07K2319/31 C07K2319/50 C07K2319/90 C07K2319/21 A61K2300/00
C07K14/575 A61P3/00 A61P3/04 A61P3/06 A61P3/08 A61P3/10 A61P9/00 A61P9/10

US: 1/1 435/252.33 435/254.2 435/254.21 435/254.23 435/320.1 435/348 435/357 435/360
435/365.1 435/367 435/68.1 435/69.7 514/5.2 514/5.3 514/6.7 514/6.8 514/6.9 514/7.2 514/7.4
514/9.1 530/387.3 530/399 536/23.4

Family:

Publication number	Publication date	Application number	Application date	
AR092456 AA	20150422	AR2013P103163	20130905	
AU2013311777 AA	20150319	AU20130311777	20130904	
AU2013311777 BB	20180201	AU20130311777	20130904	
BR112015004734 A2	20171121	BR20151104734	20130904	
CA2880929 AA	20150204	CA20132880929	20130904	
CL2015000379 A1	20150605	CL20150000379	20150217	
CN104736558 A	20150624	CN201380046749	20130904	
CR20150149 A	20150529	CR20150000149	20150319	
DOP2015000020 A	20150415	DO20150000020	20150205	
EA201590525 A1	20150730	EA20150090525	20130904	
EP2892919 A1	20150715	EP20130758851	20130904	
GT201500049 A	20160215	GT20150000049	20150227	
HK1207097 A1	20160122	HK20150107811	20150813	
ID201702530 A	20170317	ID2015P0002004	20130904	
IL237032 A0	20150331	IL20130237032	20130904	
IN01196CN2015 A	20160701	IN2015CN01196	20150226	
JP2015533483 T2	20151126	JP20150530371T	20130904	
KR20150043505 A	20150422	KR20157007317	20130904	
MA37963 A1	20180629	MA20130037963	20130904	
MX2015002985 A1	20150622	MX20150002985	20130904	
PE06482015 A1	20150525	PE20150000288	20130904	
PE20150648 A1	20150525	PE20150000288	20130904	
PH2015500194 A	20150420	PH20150500194	20150129	
SG11201500682W A1	20150227	SG20151100682	20130904	
TN2015000053 A1	20160629	TN20150000053	20150218	
TW201414750 A	20140416	TW20130132110	20130906	
US2014073563 AA	20140313	US20130019735	20130906	
US2016194371 AA	20160707	US20150965841	20151210	
US2019085043 AA	20190321	US20180047695	20180727	
UY35018 A1	20140331	UY20130035018	20130906	
WO14037373 A1	20140313	WO2013EP68239	20130904	

Priority:

EP20120306072 20120907 EP20130758851 20130904 WO2013EP68239 20130904
US20130019735 20130906 US20150965841 20151210 US20180047695 20180727

Probable Assignee: SANOFI

Assignee(s): (std): BOSCHEINEN OLIVER ; DREYER MATTHIAS ; HABERMANN PAUL ; LANGER
THOMAS ; SANOFI ; SCHAEFER HANS LUDWIG ; SOMMERFELD MARK ; SANOFI
SA

Inventor(s): (std): HABERMANN DR PAUL ; SCHAEFER DR HANS LUDWIG ; SOMMERFELD DR MARK ; LANGER DR THOMAS ; BOSCHEINEN DR OLIVER ; DREYER DR MATTHIAS ; SCHAEFER HANS LUDWING ; HANS LUDWING SCHAEFER ; THOMAS LANGER ; PAUL HABERMANN ; OLIVER BOSCHEINEN ; MARK SOMMERFELD ; MATTHIAS DREYER ; HANS LUDWIG SCHAEFER ; SCHAEFER HANS LUDWIG ; DREYER MATTHIAS ; SOMMERFELD MARK ; LANGER THOMAS ; BOSCHEINEN OLIVER ; HABERMANN PAUL

Inventor(s): EYER MATTHIAS ; DR HANS LUDWIG SCHAEFER ; DR OLIVER BOSCHEINEN ; DR PAUL HABERMANN ; DR MARK SOMMERFELD ; DR MATTHIAS DREYER ; DR THOMAS LANGER

Agent(s): WATERMARK PATENT AND TRADE MARKS ATTORNEYS; WATERMARK INTELLECTUAL PROPERTY PTY LTD; FETHERSTONHAUGH AND CO; ESTUDIO CAREY LTDA; TIMMERBEIL BJOERN; CHINA PATENT AGENT HK LTD; DRTOETI HERATY N ROOSSENO

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

10) Family number: 33118825 (US2006269553A)

© PatBase

Title: PROTEIN COMPLEX USING AN IMMUNOGLOBULIN FRAGMENT AND METHOD FOR THE PREPARATION THEREOF

Abstract:

Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.

Classifications:**International (IPC 8-9):** A61K

A61K31/365 A61K31/74

A61K38/00 A61K38/01

A61K38/04 A61K38/16

A61K38/19 A61K38/21

A61K38/22 A61K38/26

A61K38/27 A61K38/43

A61K39/00 A61K39/39

A61K39/395 A61K39/40

A61K45/06 A61K47/34

A61K47/42 A61K47/48

A61K47/68 A61P A61P1/00

A61P1/16 A61P15/00 A61P3/00

A61P3/04 A61P3/06 A61P3/10

A61P35/00 A61P37/00

A61P43/00 A61P5/06 A61P5/10

A61P5/50 A61P7/00 A61P7/06

A61P9/00 C07H21/04 C07K

C07K1/02 C07K1/107 C07K1/14

C07K14/00 C07K14/50 C07K14/505 C07K14/52 C07K14/535 C07K14/54 C07K14/555 C07K14/56

C07K14/605 C07K14/61 C07K14/62 C07K14/755 C07K14/76 C07K14/775 C07K14/805 C07K16/00

C07K16/18 C07K16/42 C07K16/46 C07K19/00 C12N1/15 C12N1/19 C12N1/21 C12N15/09

C12N15/70 C12N15/74 C12N5/06 C12N5/10 C12N9/00 C12P21/02 C12P21/06

C12P21/08 (Advanced/Invention);

A61K38/01 A61K39/395 A61K47/42 A61K47/48 A61P3/04 A61P3/06 A61P3/10 C07K1/00 C07K16/00

C07K16/18 C07K16/42 C07K19/00 C12N1/21 C12N15/09 C12N15/70 C12P21/02 (Advanced/Non-

invention);

A61K31/74 A61K38/00 A61K38/01 A61K38/16 A61K38/19 A61K38/21 A61K38/22 A61K38/26

A61K38/27 A61K38/43 A61K39/00 A61K39/39 A61K39/395 A61K47/42 A61K47/48 A61P15/00

A61P3/00 A61P35/00 A61P37/00 A61P43/00 A61P5/00 A61P7/00 A61P9/00 C07H21/00 C07K1/00

C07K14/00 C07K14/435 C07K16/00 C07K16/18 C07K16/42 C07K16/46 C07K19/00 C12N1/15

C12N1/19 C12N1/21 C12N15/09 C12N15/70 C12N15/74 C12N5/06 C12N5/10 C12N9/00 C12P21/02

C12P21/06 C12P21/08 (Core/Invention);

C12N15/09 (Core/Non-invention);

A61K A61P C07K (Subclass/Invention)

International (IPC 1-7): A61K31/365 A61K38/16 A61K38/22 A61K38/26 A61K39/395 A61K47/42

A61K47/48 A61P3/04 C07K14/00 C07K16/00 C07K16/42 C07K16/46 C07K19/00 C12N15/70

CPC: A61K2039/505 C07K16/241 C07K2317/21 C07K2317/41 C07K2317/55 C07K47/48415


C07K2317/76 A61K47/60 A61K47/48415 A61K47/48423 A61K47/48507 A61K47/50 A61K38/01

A61K47/48369 A61K47/6813 A61K47/68 C07K2317/732 C07K2317/734 C07K14/505 C07K14/535

C07K14/56 C07K14/61 C07K16/46 C07K2317/52 A61K31/137 A61K38/22 A61K38/2207 A61K38/26

A61K47/6811 A61K47/6835 A61K47/6889 A61P15/00 A61P1/00 A61P1/16 A61P3/00 A61P3/04

A61P3/06 A61P3/10 A61P5/50 A61P9/00 A61P5/06 A61P5/10 A61P7/00 A61P7/06 A61P35/00

FIG 1

A61P37/00 A61P43/00 C07K19/00 C07K2319/30

European: A61K38/22 A61K38/22A A61K38/26 A61K47/48K6P A61K47/48T2C12 A61K47/48T2C12K A61K47/48T4 A61K47/48T6 C07K16/24B C07K19/00 K61K39/50S M07K316/520 M07K316/960 M07K317/210 M07K317/410 M07K317/550 M07K317/732 M07K317/734 M07K319/30

US: 1/1 424/130.1 424/130.100S 424/133.1 424/133.100P 424/155.1 424/155.100P 424/178.1 424/178.100P 424/178.100S 424/179.1 424/179.100P 424/180.1 424/181.1 424/181.100P 424/182.1 424/195.11 424/85.1 424/85.100P 424/85.7 424/85.700S 435/188 435/188.5 435/188.500S 435/188P 435/252.3 435/252.31 435/252.33 435/252.330S 435/252.34 435/252.35 435/254.11 435/254.2 435/254.21 435/254.23 435/254.3 435/254.4 435/320.1 435/320.100S 435/326 435/326S 435/419 435/488 435/488S 435/69.1 435/69.100S 435/69.6 435/69.600S 514/1.7 514/1.700S 514/10.8 514/11.2 514/11.4 514/12 514/12.4 514/12.400S 514/12.6 514/14.8 514/15.7 514/15.700S 514/3.2 514/3.200S 514/6.7 514/7.4 514/7.400S 514/7.7 514/8.5 525/54.1 525/54.100S 530/303 530/303S 530/324 530/324S 530/350 530/351 530/351S 530/359 530/359S 530/362 530/362S 530/365 530/365S 530/380 530/383 530/383S 530/385 530/385S 530/387.1 530/387.100P 530/388.1 530/388.100P 530/388.15 530/388.150S 530/391.1 530/391.100S 530/391.7 530/391.700S 530/391.9 530/391.900S 536/23.53 536/23.530S

Family:

Publication number	Publication date	Application number	Application date	
AR069458 AA	20100120	AR2008P105187	20081128	
AT522548 E	20110915	AT20040800090T	20041113	
AT540980 E	20120115	AT20040800091T	20041113	
AT555133 E	20120515	AT20040800089T	20041113	
AU2004282984 AA	20050526	AU20040282984	20041113	
AU2004282984 AA	20050714	AU20040282984	20041113	
AU2004282984 AA	20050526	AU20040282984	20041113	
AU2004282984 AA	20050714	AU20040282984	20041113	
AU2004282984 AA	20050526	AU20040282984	20041113	
AU2004282984 AA	20050714	AU20040282984	20041113	
AU2004282984 AH	20080918	AU20040282984	20041113	
AU2004282984 BB	20110714	AU20040282984	20041113	
AU2004282985 AA	20050526	AU20040282985	20041113	
AU2004282985 AA	20050630	AU20040282985	20041113	
AU2004282985 AA	20050526	AU20040282985	20041113	
AU2004282985 AA	20050630	AU20040282985	20041113	
AU2004282985 AH	20081002	AU20040282985	20041113	
AU2004282985 BB	20080814	AU20040282985	20041113	
AU2004282985 BH	20081002	AU20040282985	20041113	
AU2008330315 AA	20090604	AU20080330315	20081128	
AU2008330315 BB	20120621	AU20080330315	20081128	
BRPI0406605 A	20051206	BR2004PI06605	20041113	
BRPI0406605 B1	20191029	BR2004PI06605	20041113	
BRPI0406606 A	20051206	BR2004PI06606	20041113	
BRPI0819864 A2	20170523	BR2008PI19864	20081128	
CA2512657 AA	20050704	CA20042512657	20041113	
CA2512657 C	20140107	CA20042512657	20041113	
CA2512933 AA	20050707	CA20042512933	20041113	
CA2512933 C	20111206	CA20042512933	20041113	
CA2706627 AA	20090604	CA20082706627	20081128	
CA2706627 C	20141118	CA20082706627	20081128	
CN101878036 A	20101103	CN200880118353	20081128	
CN101878036 B	20140514	CN200880118353	20081128	

CN103212084 A	20130724	CN201210190634	20041113	
CN103212084 B	20180713	CN201210190634	20041113	
CN108743967 A	20181106	CN201810616347	20041113	
CN1723219 A	20060118	CN200480001770	20041113	
CN1723219 B	20100526	CN200480001770	20041113	
CN1723220 A	20060118	CN200480001775	20041113	
DE602004034256 D1	20111103	DE200460034256T	20041113	
DE602004036128 D1	20120315	DE200460036128T	20041113	
DE602004037553 D1	20120621	DE200460037553T	20041113	
DE602004041810 D1	20130613	DE200460041810T	20041113	
DE602004043559 D1	20131205	DE200460043559T	20041113	
DE602004044225 D1	20140227	DE200460044225T	20041113	
DE602008033888 D1	20140925	DE200860033888T	20081128	
DK1682583 T3	20120507	DK20040800091T	20041113	
DK2227243 T3	20141006	DK20080855148T	20081128	
DK2239273 T3	20131209	DK20040006326T	20041113	
DK2239273 T3	20131209	DK20100006326T	20041113	
DK2256134 T3	20140224	DK20100009129T	20041113	
DK2256134 T3	20140224	DK20040009129T	20041113	
EP1682581 A1	20060726	EP20040800089	20041113	
EP1682581 A4	20081105	EP20040800089	20041113	
EP1682581 B1	20120425	EP20040800089	20041113	
EP1682582 A1	20060726	EP20040800090	20041113	
EP1682582 A4	20081112	EP20040800090	20041113	
EP1682582 B1	20110831	EP20040800090	20041113	
EP1682583 A1	20060726	EP20040800091	20041113	
EP1682583 A4	20081119	EP20040800091	20041113	
EP1682583 B1	20120111	EP20040800091	20041113	
EP1682584 A1	20060726	EP20040800092	20041113	
EP1682584 A4	20081105	EP20040800092	20041113	
EP1682584 B1	20130417	EP20040800092	20041113	
EP2227243 A2	20100915	EP20080855148	20081128	
EP2227243 A4	20120509	EP20080855148	20081128	
EP2227243 B1	20140813	EP20080855148	20081128	
EP2239273 A1	20101013	EP20100006326	20041113	
EP2239273 B1	20131009	EP20100006326	20041113	
EP2256134 A1	20101201	EP20100009129	20041113	
EP2256134 B1	20140108	EP20100009129	20041113	
ES2372495 T3	20120120	ES20040800090T	20041113	
ES2378167 T3	20120409	ES20040800091T	20041113	
ES2383300 T3	20120620	ES20040800089T	20041113	
ES2426169 T3	20131021	ES20040800092T	20041113	
ES2438098 T3	20140115	ES20100006326T	20041113	
ES2454666 T3	20140411	ES20100009129T	20041113	
ES2521497 T3	20141112	ES20080855148T	20081128	
HK1149570 A1	20140321	HK20110103711	20110413	
HK1149570 A1	20111007	HK20110103711	20110413	
HK1149570 B	20140321	HK20110103711	20110413	
HK1150029 A1	20111028	HK20110104223	20110427	

HK1150029 A1	20141219	HK20110104223	20110427	
HK1150029 B	20141219	HK20110104223	20110427	
HK1150612 A1	20120106	HK20110104515	20110506	
HK1150612 A1	20140711	HK20110104515	20110506	
HK1150612 B	20140711	HK20110104515	20110506	
HR20140997 T1	20141219	HR20140000997	20141017	
IL205667 A0	20101130	IL20080205667	20081128	
IL205667 A1	20161130	IL20080205667	20081128	
IN02856DN2005 A	20070316	IN2005DN02856	20050627	
IN02857DN2005 A	20070525	IN2005DN02857	20050627	
IN02912CN2010 A	20100924	IN2010CN02912	20100517	
IN227910 B	20090213	IN2005DN02856	20050627	
IN284140 B	20170616	IN2005DN02857	20050627	
IN286798 B	20170901	IN2010CN02912	20100517	
JP2007531513 T2	20071108	JP20060539396T	20041113	
JP2007532098 T2	20071115	JP20060539397T	20041113	
JP2007536211 T2	20071213	JP20060539398T	20041113	
JP2007537992 T2	20071227	JP20060539399T	20041113	
JP2011256211 A2	20111222	JP20110209594	20110926	
JP2011505355 T2	20110224	JP20100535887T	20081128	
JP2012001560 A2	20120105	JP20110202199	20110915	
JP2012224635 A2	20121115	JP20120166208	20120726	
JP4762904 B2	20110831	JP20060539397T	20041113	
JP4870569 B2	20120208	JP20060539398T	20041113	
JP5216216 B2	20130619	JP20060539399T	20041113	
JP5226080 B2	20130703	JP20100535887T	20081128	
JP5425150 B2	20140226	JP20110202199	20110915	
KR100725314 B1	20070607	KR20040092783	20041113	
KR100725315 B1	20070607	KR20040092782	20041113	
KR100775343 B1	20071108	KR20040092781	20041113	
KR101135244 B1	20120424	KR20080083194	20080826	
KR20050047030 A	20050519	KR20040092780	20041113	
KR20050047031 A	20050519	KR20040092781	20041113	
KR20050047032 A	20050519	KR20040092782	20041113	
KR20050047033 A	20050519	KR20040092783	20041113	
KR20060054252 A	20060522	KR20060036697	20060424	
KR20080098216 A	20081107	KR20070043625	20070504	
KR20090056796 A	20090603	KR20080083194	20080826	
MX2010005866 A1	20100623	MX20100005866	20081128	
MXPA05007210 A1	20060210	MX2005PA07210	20041113	
MXPA05007211 A1	20060210	MX2005PA07211	20041113	
MY155454 A	20151015	MY20100002321	20081128	
NZ585314 A	20121026	NZ20080585314	20081128	
PL2227243 T3	20150331	PL20080855148T	20081128	
PL2239273 T3	20140430	PL20100006326T	20041113	
PL2256134 T3	20140630	PL20100009129T	20041113	
PT1682583 T	20120413	PT20040800091T	20041113	
PT2227243 T	20141022	PT20080855148T	20081128	
PT2239273 T	20131210	PT20100006326T	20041113	

PT2256134 T	20140305	PT20100009129T	20041113	
RU2005120239 A	20060420	RU20050120239	20041113	
RU2005120240 A	20060420	RU20050120240	20041113	
RU2010126478 A	20120110	RU20100126478	20081128	
RU2352583 C2	20090420	RU20050120239	20041113	
RU2356909 C2	20090527	RU20050120240	20041113	
RU2446816 C2	20120410	RU20100126478	20081128	
TH137153 A	20141008	TH20081006116	20081127	
TW200936154 A	20090901	TW20080145881	20081127	
TWI403331 B	20130801	TW20080145881	20081127	
US2006269553 AA	20061130	US20040535232	20041113	
US2006275254 AA	20061207	US20040535231	20041113	
US2006276633 AA	20061207	US20040535312	20041113	
US2007041967 AA	20070222	US20040535341	20041113	
US2008085862 AA	20080410	US20070744162	20070503	
US2008124347 AA	20080529	US20070747153	20070510	
US2009238838 AA	20090924	US20070947697	20071129	
US2010255014 AA	20101007	US20100757635	20100409	
US2010261248 AA	20101014	US20100759801	20100414	
US2010330108 AA	20101230	US20080744660	20081128	
US2011245472 AA	20111006	US20110087593	20110415	
US2013288333 AA	20131031	US20130796135	20130312	
US2015025227 AA	20150122	US20140327064	20140709	
US2015025228 AA	20150122	US20140327120	20140709	
US2018326083 AA	20181115	US20180041263	20180720	
US2019269787 AA	20190905	US20190351338	20190312	
US7736653 BB	20100615	US20040535231	20041113	
US7737260 BB	20100615	US20040535232	20041113	
US8029789 BB	20111004	US20040535312	20041113	
US8110665 BB	20120207	US20100759801	20100414	
US8263084 BB	20120911	US20080744660	20081128	
US8822650 BB	20140902	US20110087593	20110415	
US8846874 BB	20140930	US20040535341	20041113	
US9750820 BB	20170905	US20140327120	20140709	
US10071166 BB	20180911	US20130796135	20130312	
US10272159 BB	20190430	US20140327064	20140709	
VN19325 A1	20180625	VN20100001327	20081128	
WO05047334 A1	20050526	WO2004KR02942	20041113	
WO05047335 A1	20050526	WO2004KR02943	20041113	
WO05047336 A1	20050526	WO2004KR02944	20041113	
WO05047337 A1	20050526	WO2004KR02945	20041113	
WO08136611 A1	20081113	WO2008KR02502	20080502	
WO09069983 A2	20090604	WO2008KR07074	20081128	
WO09069983 A3	20090820	WO2008KR07074	20081128	
ZA201003796 A	20110223	ZA20100003796	20100527	

Priority:

KR20030080299	20011113	KR20030080299	20031113	CN200480001775	20041113
EP20040800089	20041113	EP20040800090	20041113	EP20040800091	20041113
EP20040800092	20041113	JP20060539398	20041113	JP20060539396	20041113
JP20060539399	20041113	EP20100009129	20041113	EP20100006326	20041113

US20040535232	20041113	US20040535231	20041113	US20040535312	20041113
WO2004KR02942	20041113	WO2004KR02943	20041113	WO2004KR02944	20041113
WO2004KR02945	20041113	US20060535312	20060605	US20060535341	20060609
US20060535232	20060619	US20060535231	20060724	US20070744162	20070503
KR20070043625	20070504	US20070747153	20070510	US20070947697	20071129
KR20080083194	20080826	EP20080855148	20081128	US20080744660	20081128
WO2008KR07074	20081128	US20100757635	20100409	US20100759801	20100414
US20110087593	20110415	US20130796135	20130312	US20140327064	20140709
US20140327120	20140709	US20180041263	20180720	US20190351338	20190312

Probable Assignee: HANMI SCIENCE CO LTD

Assignee(s): (std): BAE SUNG MIN ; CHOI IN YOUNG ; CHOI KI DOO ; DAE HAE SONG ; EUN HEE KANG ; GWAN SUN LEE ; HANMI PHARM IND CO LTD ; HANMI PHARMACEUTICAL CO LTD ; KIM JIN S ; JUNG SUNG Y ; JUNG SUNG YOUB ; KIM DAE JIN ; KIM CHANG HWAN ; LEE GWAN S ; KWON SE C ; PARK YOUNG J ; YANG GEUN H ; KWON SE W ; LEE GWAN SUN ; YANG GEUN HEE ; KIM JIN SUN ; KWON SE CHANG ; PARK YOUNG JIN ; KIM YOUNG MIN ; LIM CHANG KI ; SONG DAE HAE ; KIM YOUNG HOON ; KIM MIN YOUNG ; YOUNG JIN PARK ; SE CHANG KWON ; MIN YOUNG KIM ; SUNG YOUB JUNG ; HANMI PHAM CO LTD ; HANMI HOLDINGS CO LTD ; KHANMI FARM IND KO LTD ; KANG EUN HEE ; HANMI SCIENCE CO LTD ; KHANMI KHOLDINGS KO LTD

Assignee(s): HANMI SCIENCE CO ; HANMI PHARMACEUTICAL CO LTD893-5 HAJEO-RIPALTAN-MYEONHWASEONG-SI445-813GYEONGGI-DOKR ; HANMI SCIENCE CO LTD550 DONGTANGIHEUNG-RODONGTAN-MYEON, HWASEONG-SI445-813GYEONGGI-DOKR ; HANMI SCIENCE CO LTD HWASEONG SI ; HANMI PHARMACEUTICAL CO ; KHANMI KHOLDINGS KO ; HANMI HOLDINGS CO LTD45, BANGI-DONGSONGPA-GU138-828SEOULKR ; HANMI HOLDINGS CO ; KHANMI FARM IND KO ; HANMI PHARM IND CO ; HANMI PHARM CO ; HANMI PHARM CO LTD ; HANMI PHAM CO

Inventor(s): (std): HEE KANG EUN ; YOUB JUNG SUNG ; JIN PARK YOUNG ; SUN LEE GWAN ; CHANG KWON SE ; YOUNG KIM MIN ; HAE SONG DAE ; MIN BAE SUNG ; KI LIM CHANG ; JIN KIM DAE ; MIN KIM YOUNG ; GWAN LEE ; YANG GEUN ; KWON SE WANG ; SUN YOUB JUNG ; KIM CHANG HW ; KIM CHAN FAN ; KANG EUN KHI ; DZUNG SUNG JUB ; PARK JANG DZIN ; KIM MIN JANG ; JUNG SUNG YOB ; KWON SE ; KIM JIN ; JUNG SUNG ; PARK YOUNG ; SONG DAC HAE ; KIM MIN YOUNG ; KANG EUN HEE ; KIM DAE DZIN ; CHOI IN JANG ; KIM CHANG KHVAN ; KIM JANG MIN ; LI GVAN SUN ; DZUNG SUNG JOUB ; KVON SE CHANG ; SONG DAE KHAE ; KWON SE W ; YANG GEUN H ; PARK YOUNG J ; KIM JIN S ; CHOI IN Y ; KIM CHANG H ; JUNG SUNG Y ; PARK YOUNG JIN ; CHOI KI DOO ; KIM JIN SUN ; YANG GEUN HEE ; SUN KIM YOUNG MIN SONG DAE HAE ; GWAN SUN LEE ; DAE HAE SONG ; LEE GWAN ; SE CHANG KWON ; CHANG KI LIM ; YOUNG MIN KIM ; SUNG MIN BAE ; DAE JIN KIM ; KWON SE CHANG ; LEE GWAN SUN ; SONG DAE HAE ; KIM DAE JIN ; LIM CHANG KI ; KIM YOUNG MIN ; KIM YOUNG HOON ; BAE SUNG MIN ; KIM YOUNG M ; KIM YOUNG H ; SONG DAE H ; LEE GWAN S ; BAE SUNG M ; KIM DAE J ; LIM CHANG K ; KWON SE C ; JUNG SUNG YOUB ; CHOI IN YOUNG ; KIM CHANG HWAN ; SUN KIM YOUNG MIN KIM DAE JIN ; SUNG YOUB JUNG ; YOUNG JIN PARK ; MIN YOUNG KIM ; EUN HEE KANG

Inventor(s): IN YOUNG CHOI ; KIM YOUNG MIN KIM DAE JIN BAE SUNG MIN LIM ; CHANG HWAN KIM ; KIM YOUNG MIN SONG DAE HAE JUNG SUNG YOUB KIM ; PARK YOUNG JIN SUWON SI ; YANG GEUN HEE SUWON SI ; LIM CHANG KI SUWON SI ; KIM YOUNG MIN YONGI SI ; SONG DAE HAE GEUMCHEON GU ; LEE GWAN SUN SONGPA GU ; KIM YOUNG MIN YONGIN SI ; JUNG SUNG YOUB SUWON SI ; KIM CHANG HWAN SUWON SI ; CHOI IN YOUNG SEONGNAM SI ; JUNG SUNG YOUB SUWON SIGYEONGGI DO ; SONG DAE HAE GEUMCHEON GOSEOUL ; LEE GWAN SUN SEOUL ; KIM YOUNG MIN YONGIN SIGEONGGI DO ; CHOI IN YOUNG SEONGNAM SIGYEONGGI DO ; KWON SE CHANG GWANGJIN GU ; SONG DAE HAEKR ; PARK YOUNG JINKR ; KANG EUN HEEKR ; JUNG SUNG YOUBKR ; LEE GWAN SUNKR ; KIM MIN YOUNGKR ; KWON SE CHANGKR ; JIN SUN KIM ; GEUN HEE YANG ; KIM CHANG ; CHOI IN ; KIM DAE ; LIM CHANG ; BAE SUNG ; KIM YOUNG ; SONG DAE ; KIM YOUNG MIN SONG DAE HAE JUNG SUNG YOUB KIM CHANG HWAN CHOI IN YOUNG KWON SE CHANG LEE GWAN SUN ; KIM YOUNG

MIN KIM DAE JIN BAE SUNG MIN LIM CHANG KI KWON SE CHANG LEE GWAN SUN

Agent(s): WRAYS; BERESKIN AND PARR LLP SENCRL SRL; MAI DOERR BESIER PATENTANWAELTE; STOLMAR AND PARTNER PATENTANWAELTE PARTG MBB; MAI DOERR BESIER; LUDERSCHMIDT SCHUELER AND PARTNER; GOODALL SCOTT; CARVAJAL Y ISABEL; ARIAS JUAN; CARPINTERO MARIO; CHINA SINDA INTELLECTUAL PROPERTY LTD; NTD PATENT AND TRADE MARK AGENCY LTD; JMB DAVIS BEN DAVID; SEED INTELLECTUAL PROPERTY LAW GROUP PLLC; SUGHRUE MION PLLC; SON MIN

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

11) Family number: 50525916 (US2013122023A)

© PatBase

Title: NOVEL LONG-ACTING GLUCAGON CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR THE PREVENTION AND TREATMENT OF OBESITY

Abstract:

Disclosed is a novel long-acting glucagon conjugate in which glucagon or its derivative is covalently linked to a polymer carrier via a non-peptide linker, and a pharmaceutical composition comprising the same as an effective ingredient useful for the prevention and treatment of obesity. Since the long-acting glucagon conjugate of the present invention shows improved in vivo durability and stability, when used in combination with an anti-obesity drug, it is possible to induce synergistic effects on the loss of body weight and decrease in food intake without causing any side-effects such as fluctuation in blood glucose level. Accordingly, the long-acting peptide conjugate of the present invention is very effective for the prevention and treatment of obesity.

Classifications:

International (IPC 8-9):


A61K31/197 A61K31/4164
A61K38/00 A61K38/22
A61K38/26 A61K38/38
A61K39/00 A61K39/385
A61K45/00 A61K45/06
A61K47/12 A61K47/32
A61K47/34 A61K47/36
A61K47/42 A61K47/48
A61K47/68 A61P3/00 A61P3/04
C07K1/00 C07K14/605
C07K17/02 (Advanced/Invention)

CPC: A61K2300/00

A61K47/6811 A61K47/6883
A61P3/00 A61P3/04
A61K31/4164 A61K38/26
A61K45/06 A61K47/68

PatBase - US2013122023 AA

Patent Application Publication May 16, 2013 Sheet 1 of 5 US 2013/0122023 A1



C07K14/605

European: A61K31/4164 A61K38/26 A61K45/06 A61K47/48T C07K14/605

US: 1/1 424/178.1 530/391.7

Family:

Publication number	Publication date	Application number	Application date	
AR082320 AA	20121128	AR2011P102650	20110721	
EP2595648 A2	20130529	EP20110809879	20110721	
EP2595648 A4	20140702	EP20110809879	20110721	
EP3248611 A1	20171129	EP20170178273	20110721	
JP2013537525 T2	20131003	JP20130520654T	20110721	
JP6076902 B2	20170208	JP20130520654T	20110721	
KR101382593 B1	20140410	KR20110070535	20110715	
KR20120010146 A	20120202	KR20110070535	20110715	
TW201309323 A	20130301	TW20110125894	20110721	
TWI593422 B	20170801	TW20110125894	20110721	
US2013122023 AA	20130516	US20110810999	20110721	
US9072794 BB	20150707	US20110810999	20110721	
WO12011752 A2	20120126	WO2011KR05375	20110721	
WO12011752 A3	20120531	WO2011KR05375	20110721	

Priority:

KR20100070484 20100721 KR20100070485 20100721 EP20110809879 20110721
WO2011KR05375 20110721

Probable Assignee: HANMI SCIENCE CO LTD

Assignee(s): (std): CHOI IN YOUNG ; HANMI HOLDINGS CO LTD ; HANMI SCIENCE CO LTD ; JUNG SUNG YOUB ; KIM DAE JIN ; KWON SE CHANG ; WOO YOUNG EUN ; LEE JONG SOO ; SHEN LING AI

Assignee(s): HANMI SCIENCE CO ; HANMI HOLDINGS CO

Inventor(s): (std): SHEN LING AI ; CHOI IN YOUNG ; WOO YOUNG EUN ; LEE JONG SOO ; JUNG SUNG YOUB ; KIM DAE JIN ; KWON SE CHANG ; LEE JONG ; SOO WOO YOUNG EUN

Agent(s): FORREST GRAHAM ROBERT; TAKANO TOSHIO; PATENT CORPORATE BODY ARUGA PATENT OFFICE; MURATA MASAKI; NAKAJIMA TOSHIO; YAMAMOTO HIROTO; SUGHRUE MION PLLC; SON MIN

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW